

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 September 2001 (27.09.2001)

PCT

(10) International Publication Number
WO 01/70738 A2

(51) International Patent Classification⁷: C07D 417/08,
A61P 37/00

(21) International Application Number: PCT/CA01/00365

(22) International Filing Date: 19 March 2001 (19.03.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/191,668 23 March 2000 (23.03.2000) US

(71) Applicant (for all designated States except US):
MERCK FROSST CANADA & CO. [CA/CA]; 16711
Trans-Canada Highway, Kirkland, Québec H9H 3L1 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **FRIESEN, Richard** [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Québec H9H 3L1 (CA). **DUCHARME, Yves** [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Québec H9H 3L1 (CA). **COTE, Bernard** [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Québec H9H 3L1 (CA). **BLOUIN, Marc** [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Québec H9H 3L1 (CA). **MARTINS, Evelyn** [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Québec H9H 3L1 (CA). **GUAY, Daniel** [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Québec H9H 3L1 (CA). **HAMEL, Pierre** [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Québec H9H 3L1 (CA). **GIRARD, Mario** [CA/CA];

16711 Trans-Canada Highway, Kirkland, Québec H9H 3L1 (CA). **FRENETTE, Richard** [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Québec H9H 3L1 (CA). **LALIBERTE, Sebastien** [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Québec H9H 3L1 (CA).

(74) Agents: **MURPHY, Kevin, P. et al.**; **SWABEY OGILVY RENAULT**, Suite 1600, 1981 McGill College Avenue, Montreal, Québec H3A 2Y3 (CA).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GII, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

A2
WO 01/70738 A2

(54) Title: TRI-ARYL-SUBSTITUTED-ETHANE PDE4 INHIBITORS

(57) Abstract: Novel ethanes substituted with i) a phenyl, ii) a thiazole, and iii) a pyridyl moiety are PDI4 inhibitors.

TITLE OF THE INVENTION

TRI-ARYL-SUBSTITUTED-ETHANE PDE4 INHIBITORS

5 BACKGROUND OF THE INVENTION

FIELD OF THE INVENTION

The present invention is directed to compounds that are tri-aryl substituted ethanes. In particular, this invention is directed to ethanes substituted with i) a phenyl, ii) 10 a thiazole, and iii) a pyridyl moiety which are phosphodiesterase-4 inhibitors.

RELATED BACKGROUND

Hormones are compounds that variously affect cellular activity. In many respects, hormones act as messengers to trigger specific cellular responses and activities. 15 Many effects produced by hormones, however, are not caused by the singular effect of just the hormone. Instead, the hormone first binds to a receptor, thereby triggering the release of a second compound that goes on to affect the cellular activity. In this scenario, the hormone is known as the first messenger while the second compound is called the second messenger. Cyclic adenosine monophosphate (adenosine 3', 5'-cyclic 20 monophosphate, "cAMP" or "cyclic AMP") is known as a second messenger for hormones including epinephrine, glucagon, calcitonin, corticotrophin, luteinizing hormone, norepinephrine, parathyroid hormone, thyroid-stimulating hormone, and vasopressin. Thus, cAMP mediates cellular responses to hormones. Cyclic AMP also mediates cellular responses to various neurotransmitters.

25 Phosphodiesterases ("PDE") are a family of enzymes that metabolize 3', 5' cyclic nucleotides to 5' nucleoside monophosphates, thereby terminating cAMP second messenger activity. A particular phosphodiesterase, phosphodiesterase-4 ("PDE4", also known as "PDE-IV"), which is a high affinity, cAMP specific, type IV PDE, has generated interest as potential targets for the development of novel anti- 30 asthmatic and anti-inflammatory compounds. PDE4 is known to exist as at least four isoenzymes, each of which is encoded by a distinct gene. Each of the four known PDE4 gene products is believed to play varying roles in allergic and/or inflammatory responses. Thus, it is believed that inhibition of PDE4, particularly the specific PDE4 isoforms that produce detrimental responses, can beneficially affect allergy and inflammation

symptoms. It would be desirable to provide novel compounds and compositions that inhibit PDE4 activity.

Inhibition of PDE4 activity is believed effective for the treatment of osteoporosis by reducing bone loss. For example, Ken-ichi Miyamoto et al., *Biochem. Pharmacology*, 54:613-617(1997) describes the effect of a PDE4 on bone loss. Therefore, it would be desirable to provide novel compounds and compositions that inhibit PDE4 activity.

A major concern with the use of PDE4 inhibitors is the side effect of emesis which has been observed for several candidate compounds as described in C.Burnouf et al., ("Burnouf"), *Ann. Rep. In Med. Chem.*, 33:91-109(1998). B.Hughes et al., *Br. J.Pharmacol.*, 118:1183-1191(1996); M.J.Perry et al., *Cell Biochem. Biophys.*, 29:113-132(1998); S.B.Christensen et al., *J.Med. Chem.*, 41:821-835(1998); and Burnouf describe the wide variation of the severity of the undesirable side effects exhibited by various compounds. As described in M.D.Houslay et al., *Adv. In Pharmacol.*, 44:225-342(1998) and D.Spina et al., *Adv. In Pharmacol.*, 44:33-89(1998), there is great interest and research of therapeutic PDE4 inhibitors.

U.S. Patent Nos. 5,622,977, 5,710,160, 5,710,170, 5,798,373, 5,849,770, and International Patent Publication No. WO 99/50262 describe tri-substituted aryl derivative PDE IV inhibitors, including tri-aryl ethane derivatives.

Compounds that include ringed systems are described by various investigators as effective for a variety of therapies and utilities. For example, International Patent Publication No. WO 98/25883 describes ketobenzamides as calpain inhibitors, European Patent Publication No. EP 811610 and U.S. Patent Nos. 5,679,712, 5,693,672 and 5,747,541 describe substituted benzoylguanidine sodium channel blockers, U.S. Patent No. 5,736,297 describes ring systems useful as a photosensitive composition. International Patent Publication WO9422852 describes quinolines as PDE4 inhibitors.

U.S. Patent Nos. 5,491,147, 5,608,070, 5,739,144, 5,776,958, 5,780,477, 5,786,354, 5,859,034, 5,866,593, 5,891,896, and International Patent Publication WO 95/35283 describe PDE4 inhibitors that are tri-substituted aryl or heteroaryl phenyl derivatives. U.S. Patent No. 5,580,888 describes PDE4 inhibitors that are styryl derivatives. U.S. Patent No. 5,550,137 describes PDE4 inhibitors that are phenylaminocarbonyl derivatives. U.S. Patent No. 5,340,827 describes PDE4 inhibitors that are phenylcarboxamide compounds. U.S. Patent No. 5,780,478 describes PDE4 inhibitors that are tetra-substituted phenyl derivatives. International Patent Publication WO 96/00215 describes substituted oxime derivatives useful as PDE4 inhibitors. U.S.

Patent No. 5,633,257 describes PDE4 inhibitors that are cyclo(alkyl and alkenyl)phenyl-alkenyl (aryl and heteroaryl) compounds.

However, there remains a need for novel compounds and compositions that therapeutically inhibit PDE4 with minimal side effects.

5


SUMMARY OF THE INVENTION

The present invention is directed to novel tri-aryl substituted ethanes. In particular, this invention is directed to ethanes substituted with i) a phenyl, ii) a thiazole, and iii) a pyridyl moiety which are phosphodiesterase-4 inhibitors. This invention also 10 provides a pharmaceutical composition which includes an effective amount of the novel tri-aryl substituted ethanes and a pharmaceutically acceptable carrier. This invention further provides a method of treatment in mammals of, for example, asthma, chronic bronchitis, chronic obstructive pulmonary disease (COPD), eosinophilic granuloma, psoriasis and other benign or malignant proliferative skin diseases, endotoxic shock (and 15 associated conditions such as laminitis and colic in horses), septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, inflammatory arthritis, chronic glomerulonephritis, atopic dermatitis, urticaria, adult respiratory distress syndrome, infant respiratory distress syndrome, chronic obstructive pulmonary disease in animals, diabetes insipidus, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, 20 arterial restenosis, ortherosclerosis, atherosclerosis, neurogenic inflammation, pain, cough, rheumatoid arthritis, ankylosing spondylitis, transplant rejection and graft versus host disease, hypersecretion of gastric acid, bacterial, fungal or viral induced sepsis or septic shock, inflammation and cytokine-mediated chronic tissue degeneration, 25 osteoarthritis, cancer, cachexia, muscle wasting, depression, memory impairment, tumour growth, cancerous invasion of normal tissues, osteoporosis, and bone loss by the administration of an effective amount of the novel ethanes substituted with i) a phenyl, ii) a thiazole, and iii) a pyridyl moiety which are phosphodiesterase-4 inhibitors

DETAILED DESCRIPTION OF THE INVENTION

30

A compound of this invention is represented by Formula (I):



or a pharmaceutically acceptable salt thereof, wherein

5 R^1 is C_{1-6} alkyl or C_{3-6} cycloalkyl, optionally substituted with 1-4 independent halogen;

R^2 is C_{1-6} alkyl or C_{3-6} cycloalkyl, optionally substituted with 1-4 independent halogen;

R^3 is C_{1-4} alkyl, C_{3-6} cycloalkyl, heteroaryl, or phenyl, any of which 10 optionally substituted independently with 1-4 independent halogen or C_{1-6} alkyl;

R^4 is H or C_{1-4} alkyl, said alkyl optionally substituted with 1-4 independent halogen;

R^P is H, halogen, nitrile, or a C_{1-6} alkyl group, said alkyl optionally substituted with 1-4 independent halogen;

15 n is 0 or 1; and

 when R^3 and R^4 are connected to each other through X, then R^3 and R^4 are each C_1 alkyl, and X is C_{0-4} alkyl.

According to one aspect, a compound of this invention is represented by 20 formula (I) or a pharmaceutically acceptable salt thereof, wherein

R^1 is C_{1-6} alkyl, optionally substituted with 1-4 independent halogen;

R^2 is C_{1-6} alkyl or C_{3-6} cycloalkyl, optionally substituted with 1-4 independent halogen;

R^3 is C_{1-4} alkyl, C_{3-6} cycloalkyl, heteroaryl, or phenyl, any of which 25 optionally substituted independently with 1-4 independent halogen or C_{1-6} alkyl;

R^4 is H or C₁₋₄alkyl, said alkyl optionally substituted with 1-4 independent halogen;

R^P is H, halogen, nitrile, or a C₁₋₆alkyl group, said alkyl optionally substituted with 1-4 independent halogen;

5 n is 0 or 1; and

when R^3 and R^4 are connected to each other through X, then R^3 and R^4 are each C₁alkyl, and X is C₀₋₄alkyl.

10 According to one embodiment of this aspect,

R^1 is C₁₋₆alkyl, optionally substituted with 1-4 independent halogen;

R^2 is C₁₋₆alkyl, optionally substituted with 1-4 independent halogen;

R^3 is C₁₋₄alkyl, C₃₋₆cycloalkyl, heteroaryl, or phenyl, any of which optionally substituted independently with 1-4 independent halogen or C₁₋₆alkyl;

R^4 is H or C₁₋₄alkyl, said alkyl optionally substituted with 1-4

15 independent halogen;

R^P is H, halogen, nitrile, or a C₁₋₆alkyl group, said alkyl optionally substituted with 1-4 independent halogen;

n is 0 or 1; and

20 when R^3 and R^4 are connected to each other through X, then R^3 and R^4 are each C₁alkyl, and X is C₀₋₄alkyl.

According to another embodiment of this aspect,

R^1 is C₁₋₆alkyl, optionally substituted with 1-4 independent halogen;

R^2 is C₁₋₆alkyl, optionally substituted with 1-4 independent halogen;

25 R^3 is C₁₋₄alkyl, optionally substituted independently with 1-4 independent halogen or C₁₋₆alkyl;

R^4 is H or C₁₋₄alkyl, said alkyl optionally substituted with 1-4

independent halogen;

R^P is H, halogen, nitrile, or a C₁₋₆alkyl group, said alkyl optionally

30 substituted with 1-4 independent halogen; and

n is 0 or 1.

According to yet another embodiment of this aspect,

R^1 is C₁₋₆alkyl, optionally substituted with 1-4 independent halogen;

35 R^2 is C₁₋₆alkyl, optionally substituted with 1-4 independent halogen;

5 R³ is C₃-6cycloalkyl, optionally substituted independently with 1-4 independent halogen or C₁-6alkyl;

 R⁴ is H or C₁-4alkyl, said alkyl optionally substituted with 1-4 independent halogen;

 R^P is H, halogen, nitrile, or a C₁-6alkyl group, said alkyl optionally substituted with 1-4 independent halogen; and

 n is 0 or 1.

10 According to an embodiment of this aspect,

 R¹ is C₁-6alkyl, optionally substituted with 1-4 independent halogen;

 R² is C₁-6alkyl, optionally substituted with 1-4 independent halogen;

 R³ is heteroaryl, optionally substituted independently with 1-4 independent halogen or C₁-6alkyl;

 R⁴ is H or C₁-4alkyl, said alkyl optionally substituted with 1-4 independent halogen;

15 R^P is H, halogen, nitrile, or a C₁-6alkyl group, said alkyl optionally substituted with 1-4 independent halogen; and

 n is 0 or 1.

20 According to an embodiment of this aspect,

 R¹ is C₁-6alkyl, optionally substituted with 1-4 independent halogen;

 R² is C₁-6alkyl, optionally substituted with 1-4 independent halogen;

 R³ is phenyl, optionally substituted independently with 1-4 independent halogen or C₁-6alkyl;

25 R⁴ is H or C₁-4alkyl, said alkyl optionally substituted with 1-4 independent halogen;

 R^P is H, halogen, nitrile, or a C₁-6alkyl group, said alkyl optionally substituted with 1-4 independent halogen; and

 n is 0 or 1.

30 According to still another embodiment of this aspect,

 R¹ is C₁-6alkyl, optionally substituted with 1-4 independent halogen;

 R² is C₁-6alkyl, optionally substituted with 1-4 independent halogen;

 R³ and R⁴ are connected to each other through X;

 R³ and R⁴ are each C₁alkyl;

X is C₀₋₄alkyl;

R^P is H, halogen, nitrile, or a C₁₋₆alkyl group, said alkyl optionally substituted with 1-4 independent halogen; and
n is 0 or 1.

5

According to another embodiment of this aspect,

R¹ is C₁₋₆alkyl, optionally substituted with 1-4 independent halogen;

R² is C₃₋₆cycloalkyl, optionally substituted with 1-4 independent halogen;

R³ is C₁₋₄alkyl, C₃₋₆cycloalkyl, heteroaryl, or phenyl, any of which

10 optionally substituted independently with 1-4 independent halogen or C₁₋₆alkyl;

R⁴ is H or C₁₋₄alkyl, said alkyl optionally substituted with 1-4

independent halogen;

R^P is H, halogen, nitrile, or a C₁₋₆alkyl group, said alkyl optionally substituted with 1-4 independent halogen;

15 n is 0 or 1; and

when R³ and R⁴ are connected to each other through X, then R³ and R⁴ are each C₁alkyl, and X is C₀₋₄alkyl.

According to another embodiment of this aspect,

20 R¹ is C₁₋₆alkyl, optionally substituted with 1-4 independent halogen;

R² is C₃₋₆cycloalkyl, optionally substituted with 1-4 independent halogen;

R³ is C₁₋₄alkyl, optionally substituted independently with 1-4

independent halogen or C₁₋₆alkyl;

R⁴ is H or C₁₋₄alkyl, said alkyl optionally substituted with 1-4

25 independent halogen;

R^P is H, halogen, nitrile, or a C₁₋₆alkyl group, said alkyl optionally

substituted with 1-4 independent halogen; and

n is 0 or 1.

30

According to yet another embodiment of this aspect,

R¹ is C₁₋₆alkyl, optionally substituted with 1-4 independent halogen;

R² is C₃₋₆cycloalkyl, optionally substituted with 1-4 independent halogen;

R³ is C₃₋₆cycloalkyl, optionally substituted independently with 1-4

independent halogen or C₁₋₆alkyl;

R⁴ is H or C₁₋₄alkyl, said alkyl optionally substituted with 1-4 independent halogen;

R^P is H, halogen, nitrile, or a C₁₋₆alkyl group, said alkyl optionally substituted with 1-4 independent halogen; and

5 n is 0 or 1.

According to an embodiment of this aspect,

R¹ is C₁₋₆alkyl, optionally substituted with 1-4 independent halogen;

R² is C₃₋₆cycloalkyl, optionally substituted with 1-4 independent halogen;

10 R³ is heteroaryl, optionally substituted independently with 1-4 independent halogen or C₁₋₆alkyl;

R⁴ is H or C₁₋₄alkyl, said alkyl optionally substituted with 1-4 independent halogen;

15 R^P is H, halogen, nitrile, or a C₁₋₆alkyl group, said alkyl optionally substituted with 1-4 independent halogen; and

n is 0 or 1.

According to an embodiment of this aspect,

R¹ is C₁₋₆alkyl, optionally substituted with 1-4 independent halogen;

20 R² is C₃₋₆cycloalkyl, optionally substituted with 1-4 independent halogen;

R³ is phenyl, optionally substituted independently with 1-4 independent

halogen or C₁₋₆alkyl;

25 R⁴ is H or C₁₋₄alkyl, said alkyl optionally substituted with 1-4 independent halogen;

R^P is H, halogen, nitrile, or a C₁₋₆alkyl group, said alkyl optionally substituted with 1-4 independent halogen; and

n is 0 or 1.

According to still another embodiment of this aspect,

30 R¹ is C₁₋₆alkyl, optionally substituted with 1-4 independent halogen;

R² is C₃₋₆cycloalkyl, optionally substituted with 1-4 independent halogen;

R³ and R⁴ are connected to each other through X;

R³ and R⁴ are each C₁alkyl;

X is C₀₋₄alkyl;

R^P is H, halogen, nitrile, or a C₁-6alkyl group, said alkyl optionally substituted with 1-4 independent halogen; and
n is 0 or 1.

5 As used herein, "alkyl" as well as other groups having the prefix "alk" such as, for example, alkoxy, alkanoyl, alkenyl, alkynyl and the like, means carbon chains which may be linear or branched or combinations thereof. Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec- and tert-butyl, pentyl, hexyl, heptyl and the like. "Alkenyl", "alkynyl" and other like terms include carbon chains containing
10 at least one unsaturated C-C bond.

The term "cycloalkyl" means carbocycles containing no heteroatoms, and includes mono-, bi- and tricyclic saturated carbocycles, as well as fused ring systems. Such fused ring systems can include one ring that is partially or fully unsaturated such as a benzene ring to form fused ring systems such as benzofused carbocycles. Cycloalkyl
15 includes such fused ring systems as spirofused ring systems. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, decahydronaphthalene, adamantine, indanyl, indenyl, fluorenyl, 1,2,3,4-tetrahydronaphthalene and the like. Similarly, "cycloalkenyl" means carbocycles containing no heteroatoms and at least one
20 non-aromatic C-C double bond, and include mono-, bi- and tricyclic partially saturated carbocycles, as well as benzofused cycloalkenes. Examples of cycloalkenyl include cyclohexenyl, indenyl, and the like.

The term "aryl" means an aromatic substituent that is a single ring or multiple rings fused together. When formed of multiple rings, at least one of the constituent rings is aromatic. The preferred aryl substituents are phenyl and naphthyl
25 groups.

The term "cycloalkyloxy" unless specifically stated otherwise includes a cycloalkyl group connected by a short C₁-C₂alkyl length to the oxy connecting atom.

The term "C₀-C₆alkyl" includes alkyls containing 6, 5, 4, 3, 2, 1, or no carbon atoms. An alkyl with no carbon atoms is a hydrogen atom substituent.

30 The term "hetero" unless specifically stated otherwise includes one or more N, O, or S atoms. Heterocycloalkyl and heteroaryl are ring systems that contain one or more O, S, or N atoms in the ring, including mixtures of such atoms. The hetero atoms replace ring carbon atoms. Thus, for example, a heterocycloC₅alkyl is a five member ring containing from 5 to no carbon atoms. The term "heteroaryl" means an aryl group

that has at least one heteroatom in the ring. The preferred heteroaryl groups are 5 and 6 member rings having 1-4 heteroatoms independently selected from N, O, or S

The term "amine" unless specifically stated otherwise includes primary, secondary and tertiary amines.

5 The term "halogen" includes fluorine, chlorine, bromine and iodine atoms.

The term "optionally substituted" is intended to include both substituted and unsubstituted. Thus, for example, optionally substituted aryl could represent a pentafluorophenyl or a phenyl ring. Further, optionally substituted multiple moieties such as, for example, alkylaryl are intended to mean that the aryl and the aryl groups are 10 optionally substituted. If only one of the multiple moieties is optionally substituted then it will be specifically recited such as "an alkylaryl, the aryl optionally substituted with halogen or hydroxyl."

Compounds described herein contain one or more double bonds and may thus give rise to cis/trans isomers as well as other conformational isomers. The present 15 invention includes all such possible isomers as well as mixtures of such isomers.

Compounds described herein can contain one or more asymmetric centers and may thus give rise to diastereomers and optical isomers. The present invention includes all such possible diastereomers as well as their racemic mixtures, their substantially pure resolved enantiomers, all possible geometric isomers, and 20 pharmaceutically acceptable salts thereof. The above Formula (I) is shown without a definitive stereochemistry at certain positions. The present invention includes all stereoisomers of Formula (I) and pharmaceutically acceptable salts thereof. Further, mixtures of stereoisomers as well as isolated specific stereoisomers are also included. During the course of the synthetic procedures used to prepare such compounds, or in 25 using racemization or epimerization procedures known to those skilled in the art, the products of such procedures can be a mixture of stereoisomers.

The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids. When the compound of the present invention is acidic, its corresponding salt can be conveniently prepared from 30 pharmaceutically acceptable non-toxic bases, including inorganic bases and organic bases. Salts derived from such inorganic bases include aluminum, ammonium, calcium, copper (ic and ous), ferric, ferrous, lithium, magnesium, manganese (ic and ous), potassium, sodium, zinc and the like salts. Particularly preferred are the ammonium, calcium, magnesium, potassium and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary 35

amines, as well as cyclic amines and substituted amines such as naturally occurring and synthesized substituted amines. Other pharmaceutically acceptable organic non-toxic bases from which salts can be formed include ion exchange resins such as, for example, arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-

5 diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the like.

10 When the compound of the present invention is basic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include, for example, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, 15 methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid and the like. Particularly preferred are citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric, and tartaric acids.

20 The pharmaceutical compositions of the present invention comprise a compound represented by Formula (I) (or pharmaceutically acceptable salts thereof) as an active ingredient, a pharmaceutically acceptable carrier and optionally other therapeutic ingredients or adjuvants. Such additional therapeutic ingredients include, for example, i) Leukotriene receptor antagonists, ii) Leukotriene biosynthesis inhibitors, and iii) M2/M3 antagonists. The compositions include compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, 25 although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered. The pharmaceutical compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.

30 Creams, ointments, jellies, solutions, or suspensions containing the compound of Formula I can be employed for topical use. Mouth washes and gargles are included within the scope of topical use for the purposes of this invention.

35 Dosage levels from about 0.01mg/kg to about 140mg/kg of body weight per day are useful in the treatment of conditions such as asthma, chronic bronchitis, chronic obstructive pulmonary disease (COPD), eosinophilic granuloma, psoriasis and other benign or malignant proliferative skin diseases, endotoxic shock (and associated

conditions such as laminitis and colic in horses), septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, inflammatory arthritis, chronic glomerulonephritis, atopic dermatitis, urticaria, adult respiratory distress syndrome, infant respiratory distress syndrome, chronic obstructive pulmonary disease in animals, diabetes 5 insipidus, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, arterial restenosis, ortherosclerosis, atherosclerosis, neurogenic inflammation, pain, cough, rheumatoid arthritis, ankylosing spondylitis, transplant rejection and graft versus host disease, hypersecretion of gastric acid, bacterial, fungal or viral induced sepsis or septic shock, inflammation and cytokine-mediated chronic tissue degeneration, osteoarthritis, cancer, 10 cachexia, muscle wasting, depression, memory impairment, tumour growth and cancerous invasion of normal tissues which are responsive to PDE4 inhibition, or alternatively about 0.5mg to about 7g per patient per day. For example, inflammation may be effectively treated by the administration of from about 0.01mg to 50mg of the compound per kilogram of body weight per day, or alternatively about 0.5mg to about 3.5g per patient 15 per day. Further, it is understood that the PDE4 inhibiting compounds of this invention can be administered at prophylactically effective dosage levels to prevent the above-recited conditions.

The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and 20 the particular mode of administration. For example, a formulation intended for the oral administration to humans may conveniently contain from about 0.5mg to about 5g of active agent, compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition. Unit dosage forms will generally contain between from about 1mg to about 500mg of the active 25 ingredient, typically 25mg, 50mg, 100mg, 200mg, 300mg, 400mg, 500mg, 600mg, 800mg or 1000mg.

It is understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the age, body weight, general 30 health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.

In practice, the compounds represented by Formula (I), or pharmaceutically acceptable salts thereof, of this invention can be combined as the active 35 ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral

(including intravenous). Thus, the pharmaceutical compositions of the present invention can be presented as discrete units suitable for oral administration such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient. Further, the compositions can be presented as a powder, as granules, as a solution, as a

5 suspension in an aqueous liquid, as a non-aqueous liquid, as an oil-in-water emulsion or as a water-in-oil liquid emulsion. In addition to the common dosage forms set out above, the compound represented by Formula (I), or pharmaceutically acceptable salts thereof, may also be administered by controlled release means and/or delivery devices. The

10 compositions may be prepared by any of the methods of pharmacy. In general, such methods include a step of bringing into association the active ingredient with the carrier that constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both. The product can then be conveniently shaped into the desired presentation.

15 Thus, the pharmaceutical compositions of this invention may include a pharmaceutically acceptable carrier and a compound or a pharmaceutically acceptable salt of Formula (I). The compounds of Formula (I), or pharmaceutically acceptable salts thereof, can also be included in pharmaceutical compositions in combination with one or more other therapeutically active compounds.

20 The pharmaceutical carrier employed can be, for example, a solid, liquid, or gas. Examples of solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid. Examples of liquid carriers are sugar syrup, peanut oil, olive oil, and water. Examples of gaseous carriers include carbon dioxide and nitrogen.

25 In preparing the compositions for oral dosage form, any convenient pharmaceutical media may be employed. For example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like may be used to form oral liquid preparations such as suspensions, elixirs and solutions; while carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants,

30 binders, disintegrating agents, and the like may be used to form oral solid preparations such as powders, capsules and tablets. Because of their ease of administration, tablets and capsules are the preferred oral dosage units whereby solid pharmaceutical carriers are employed. Optionally, tablets may be coated by standard aqueous or nonaqueous techniques

A tablet containing the composition of this invention may be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants. Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent. Each tablet preferably contains from about 0.1mg to about 500mg of the active ingredient and each cachet or capsule preferably containing from about 0.1mg to about 500mg of the active ingredient.

10 Pharmaceutical compositions of the present invention suitable for parenteral administration may be prepared as solutions or suspensions of the active compounds in water. A suitable surfactant can be included such as, for example, hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Further, a preservative can be included to prevent the detrimental growth of microorganisms.

15 Pharmaceutical compositions of the present invention suitable for injectable use include sterile aqueous solutions or dispersions. Furthermore, the compositions can be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions. In all cases, the final injectable form must be sterile and must be effectively fluid for easy syringability. The pharmaceutical compositions must be stable under the conditions of manufacture and storage; thus, preferably should be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g. glycerol, propylene glycol and liquid polyethylene glycol), vegetable oils, and suitable mixtures thereof.

20 Pharmaceutical compositions of the present invention can be in a form suitable for topical use such as, for example, an aerosol, cream, ointment, lotion, dusting powder, or the like. Further, the compositions can be in a form suitable for use in transdermal devices. These formulations may be prepared, utilizing a compound represented by Formula (I) of this invention, or pharmaceutically acceptable salts thereof, via conventional processing methods. As an example, a cream or ointment is prepared by mixing hydrophilic material and water, together with about 5 wt% to about 10 wt% of the compound, to produce a cream or ointment having a desired consistency.

25 Pharmaceutical compositions of this invention can be in a form suitable for rectal administration wherein the carrier is a solid. It is preferable that the mixture

forms unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art. The suppositories may be conveniently formed by first admixing the composition with the softened or melted carrier(s) followed by chilling and shaping in moulds.

5 In addition to the aforementioned carrier ingredients, the pharmaceutical formulations described above may include, as appropriate, one or more additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including anti-oxidants) and the like. Furthermore, other adjuvants can be included to render the formulation isotonic with the blood of the
10 intended recipient. Compositions containing a compound described by Formula (I), or pharmaceutically acceptable salts thereof, may also be prepared in powder or liquid concentrate form.

15 The compounds and pharmaceutical compositions of this invention have been found to exhibit biological activity as PDE4 inhibitors. Accordingly, another aspect of the invention is the treatment in mammals of, for example, asthma, chronic bronchitis, chronic obstructive pulmonary disease (COPD), eosinophilic granuloma, psoriasis and other benign or malignant proliferative skin diseases, endotoxic shock (and associated conditions such as laminitis and colic in horses), septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, inflammatory arthritis, chronic
20 glomerulonephritis, atopic dermatitis, urticaria, adult respiratory distress syndrome, chronic obstructive pulmonary disease in animals, diabetes insipidus, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, arterial restenosis, ortherosclerosis, atherosclerosis, neurogenic inflammation, pain, cough, rheumatoid arthritis, ankylosing spondylitis, transplant rejection and graft versus host disease, hypersecretion of gastric
25 acid, bacterial, fungal or viral induced sepsis or septic shock, inflammation and cytokine-mediated chronic tissue degeneration, osteoarthritis, cancer, cachexia, muscle wasting, depression, memory impairment, tumour growth and cancerous invasion of normal tissues – maladies that are amenable to amelioration through inhibition of the PDE4 isoenzyme and the resulting elevated cAMP levels – by the administration of an
30 effective amount of the compounds of this invention. The term "mammals" includes humans, as well as other animals such as, for example, dogs, cats, horses, pigs, and cattle. Accordingly, it is understood that the treatment of mammals other than humans is the treatment of clinical correlating afflictions to those above recited examples that are human afflictions.

Further, as described above, the compound of this invention can be utilized in combination with other therapeutic compounds. In particular, the combinations of the PDE4 inhibiting compound of this invention can be advantageously used in combination with i) Leukotriene receptor antagonists, ii) Leukotriene biosynthesis inhibitors, or iii) M2/M3 antagonists.

ASSAYS DEMONSTRATING BIOLOGICAL ACTIVITY

LPS AND FMLP-INDUCED TNF- α AND LTB4 ASSAYS IN HUMAN WHOLE 10 BLOOD

Whole blood provides a protein and cell-rich milieu appropriate for the study of biochemical efficacy of anti-inflammatory compounds such as PDE4-selective inhibitors. Normal non-stimulated human blood does not contain detectable levels of TNF- α and LTB4. Upon stimulation with LPS, activated monocytes express and secrete 15 TNF- α up to 8 hours and plasma levels remain stable for 24 hours. Published studies have shown that inhibition of TNF- α by increasing intracellular cAMP via PDE4 inhibition and/or enhanced adenylyl cyclase activity occurs at the transcriptional level. LTB4 synthesis is also sensitive to levels of intracellular cAMP and can be completely inhibited by PDE4-selective inhibitors. As there is little LTB4 produced during a 24 hour 20 LPS stimulation of whole blood, an additional LPS stimulation followed by fMLP challenge of human whole blood is necessary for LTB4 synthesis by activated neutrophils. Thus, by using the same blood sample, it is possible to evaluate the potency of a compound on two surrogate markers of PDE4 activity in the whole blood by the following procedure.

25 Fresh blood was collected in heparinized tubes by venipuncture from healthy human volunteers (male and female). These subjects had no apparent inflammatory conditions and had not taken any NSAIDs for at least 4 days prior to blood collection. 500 μ L aliquots of blood were pre-incubated with either 2 μ L of vehicle (DMSO) or 2 μ L of test compound at varying concentrations for 15 minutes at 37°C. This 30 was followed by the addition of either 10 μ L vehicle (PBS) as blanks or 10 μ L LPS (1 μ g/mL final concentration, #L-2630 (Sigma Chemical Co., St. Louis, MO) from *E. coli*, serotype 0111:B4; diluted in 0.1% w/v BSA (in PBS)). After 24 hours of incubation at 37°C, another 10 μ L of PBS (blank) or 10 μ L of LPS (1 μ g/mL final concentration) was added to blood and incubated for 30 minutes at 37°C. The blood was then challenged 35 with either 10 μ L of PBS (blank) or 10 μ L of fMLP (1 μ M final concentration, #F-3506

(Sigma); diluted in 1% w/v BSA (in PBS)) for 15 minutes at 37°C. The blood samples were centrifuged at 1500xg for 10 minutes at 4°C to obtain plasma. A 50µL aliquot of plasma was mixed with 200µL methanol for protein precipitation and centrifuged as above. The supernatant was assayed for LTB4 using an enzyme immunoassay kit

5 (#520111 from Cayman Chemical Co., Ann Arbor, MI) according to the manufacturer's procedure. TNF- α was assayed in diluted plasma (in PBS) using an ELISA kit (Cistron Biotechnology, Pine Brook, NJ) according to manufacturer's procedure. The IC₅₀ values of Examples 1-36 generally ranged from 0.01 µM to 20 µM.

10 **ANTI-ALLERGIC ACTIVITY IN VIVO**

Compounds of the invention have been tested for effects on an IgE-mediated allergic pulmonary inflammation induced by inhalation of antigen by sensitized guinea pigs. Guinea pigs were initially sensitized to ovalbumin under mild cyclophosphamide-induced immunosuppression, by intraperitoneal injection of antigen in combinations with aluminum hydroxide and pertussis vaccine. Booster doses of antigen were given two and four weeks later. At six weeks, animals were challenged with aerosolized ovalbumin while under cover of an intraperitoneally administered anti-histamine agent (mepyramine). After a further 48h, bronchial alveolar lavages (BAL) were performed and the numbers of eosinophils and other leukocytes in the BAL fluids were counted. The lungs were also removed for histological examination for inflammatory damage. Administration of compounds of the Examples (0.001-10mg/kg i.p. or p.o.), up to three times during the 48h following antigen challenge, lead to a significant reduction in the eosinophilia and the accumulation of other inflammatory leukocytes. There was also less inflammatory damage in the lungs of animals treated with compounds of the Examples.

SPA BASED PDE ACTIVITY ASSAY PROTOCOL

Compounds which inhibit the hydrolysis of cAMP to AMP by the type-IV cAMP-specific phosphodiesterases were screened in a 96-well plate format as follows:

30 In a 96 well-plate at 30°C was added the test compound (dissolved in 2µL DMSO), 188µL of substrate buffer containing [2,8-³H] adenosine 3',5'-cyclic phosphate (cAMP, 100nM to 50µM), 10mM MgCl₂, 1mM EDTA, 50mM Tris, pH 7.5. The reaction was initiated by the addition of 10µL of human recombinant PDE4 (the amount was controlled so that ~10% product was formed in 10min.). The reaction was stopped 35 after 10min. by the addition of 1mg of PDE-SPA beads (Amersham Pharmacia Biotech,

Inc., Piscataway, NJ). The product AMP generated was quantified on a Wallac Microbeta® 96-well plate counter (EG&G Wallac Co., Gaithersburg, MD). The signal in the absence of enzyme was defined as the background. 100% activity was defined as the signal detected in the presence of enzyme and DMSO with the background subtracted.

5 Percentage of inhibition was calculated accordingly. IC₅₀ value was approximated with a non-linear regression fit using the standard 4-parameter/multiple binding sites equation from a ten point titration.

10 The IC₅₀ values of Examples 1-36 were determined with 100nM cAMP using the purified GST fusion protein of the human recombinant phosphodiesterase IVa (met-248) produced from a baculovirus/Sf-9 expression system. The IC₅₀ values of Examples 1-36 generally ranged from 0.05nm to 200nm.

15 The examples that follow are intended as an illustration of certain preferred embodiments of the invention and no limitation of the invention is implied.

20 Unless specifically stated otherwise, the experimental procedures were performed under the following conditions. All operations were carried out at room or ambient temperature - that is, at a temperature in the range of 18-25°C. Evaporation of solvent was carried out using a rotary evaporator under reduced pressure (600-4000pascals: 4.5-30mm. Hg) with a bath temperature of up to 60°C. The course of reactions was followed by thin layer chromatography (TLC) and reaction times are given for illustration only. Melting points are uncorrected and 'd' indicates decomposition. The melting points given are those obtained for the materials prepared as described.

25 Polymorphism may result in isolation of materials with different melting points in some preparations. The structure and purity of all final products were assured by at least one of the following techniques: TLC, mass spectrometry, nuclear magnetic resonance (NMR) spectrometry or microanalytical data. Yields are given for illustration only. When given, NMR data is in the form of delta (δ) values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as internal standard, determined at 300MHz, 400MHz or 500MHz using the indicated solvent. Conventional abbreviations used for signal shape are: s. singlet; d. doublet; t. triplet; m. multiplet; br. broad; etc. In addition, "Ar" signifies an aromatic signal. Chemical symbols have their usual meanings; the following abbreviations have also been used: v (volume), w (weight), b.p. (boiling point), m.p. (melting point), L (liter(s)), mL (milliliters), g (gram(s)), mg (milligrams(s)), mol (moles), mmol (millimoles), eq (equivalent(s)).

Methods of Synthesis

The compounds of Formula (I) of the present invention can be prepared according to the synthetic routes outlined in Schemes 1 to 3 below and by following the methods described therein. It is obvious to one skilled in the art that resolution of compounds bearing stereogenic centers, such as **VII**, **XIII** to **XVI** for example, or compounds of Formula **I** and **Ia**, can be accomplished by one of several methods, including HPLC with a chiral column, or formation and crystallization of a salt prepared by reaction of the compound with a chiral acid or base. The substituents are the same as in Formula (I) except where defined otherwise. It is apparent that R^P is readily incorporated into the compounds of this invention by starting with the appropriately substituted alkyl pyridylacetate reactant.

Scheme 1


15 The thiazole tertiary alcohols of Formula I may be prepared in a multi-step sequence from the requisite dialkoxyaldehyde **III** and an appropriately substituted thiazole **II** as presented in Scheme 1 below. Addition of a metalated thiazole, prepared by regioselective metalation of thiazole **II** with a base such as n-butyllithium in a suitable solvent such as ether or THF, to **III** provides secondary alcohol **IV**. Conversion of **IV** 20 into the corresponding secondary chloride or bromide **V** is accomplished by reaction with an appropriate halogenating reagent, such as thionyl chloride or thionyl bromide, and an organic base, such as pyridine, diisopropylethylamine or triethylamine, in an organic solvent such as dichloromethane or toluene. Alkylation of the anion derived from deprotonation of an alkyl pyridylacetate with an appropriate base, such as lithium, sodium 25 or potassium bis(trimethylsilyl)amide, with the halide **V** in an appropriate organic solvent such as THF and/or HMPA (hexamethylphosphoramide), provides the ester **VI**. Ester **VI** is decarboxylated by one of several methods to give the pyridine **VII**.

In one method, heating **VI** in the presence of aqueous hydroxide, such as sodium hydroxide, in a mixture of protic and aprotic organic solvents, such as methanol 30 or ethanol and THF, followed by acidification of the intermediate carboxylic acid with mineral acid, such as hydrochloric acid, provides **VII**. Alternatively, heating the carboxylic acid in an organic solvent such as dimethylsulfoxide provides **VII**.

Removal of the alcohol protecting group, for example by treating with an organic acid such as trifluoroacetic acid in an organic solvent such as dichloromethane (if

P = 2-(trimethylsilyl)ethoxymethoxy), affords the pyridines of Formula Ia of the present invention. Reaction of Ia with an oxidizing agent, such as m-CPBA (meta-chloroperoxybenzoic acid) or MMPP (monoperoxyphthalic acid, magnesium salt) provides the N-oxides of Formula I of the present invention. Alternatively, oxidation of 5 VII as described above for Ia, followed by deprotection affords the N-oxides of Formula I of the present invention.

Scheme 1



10


Scheme 2

Alternatively, compounds of Formula I can be prepared using the route described in Scheme 2 below. Alkylation of the anion derived from deprotonation of an

alkyl pyridylacetate *N*-oxide with an appropriate base, such as lithium, sodium or potassium bis(trimethylsilyl)amide, with the secondary halide **V** in an appropriate organic solvent such as THF and/or HMPA, provides the ester **VIII**. Decarboxylation and deprotection as described in Scheme 1 provides the *N*-oxides of Formula **I** of the present invention.

5

Scheme 2




10 Scheme 3

The thiazole tertiary alcohols of Formula **I** may also be prepared in a multi-step sequence from the requisite dialkoxyaldehyde **III** and an appropriately substituted thiazole **IX** as presented in Scheme 3 below via the intermediacy of the aldehyde **XIV**. Addition of a metalated thiazole, prepared by regioselective metalation of **IX** in a suitable solvent such as ether or THF, to **III** provides secondary alcohol **X**. Conversion of **X** into the corresponding secondary chloride or bromide **XI** is accomplished by reaction with an appropriate halogenating reagent, such as thionyl chloride or thionyl bromide, and an organic base, such as pyridine, diisopropylethylamine or triethylamine, in an organic solvent such as dichloromethane or toluene. Alkylation of the anion derived from deprotonation of an alkyl pyridylacetate with an appropriate base, such as lithium, sodium or potassium bis(trimethylsilyl)amide, with the halide **XI** in an appropriate organic solvent such as THF and/or HMPA, provides the ester **XII**. Ester **XII** is decarboxylated as described in Scheme 1 above to give **XIII**. Removal of the aldehyde protecting group by reaction of **XIII** with an acid, such as hydrochloric acid or *p*-toluenesulfonic acid, provides aldehyde **XIV**. Treatment of aldehyde **XIV** with a nucleophilic reagent, such as an organolithium, organocerium or Grignard reagent, in an organic solvent, such as ether or THF, provides the secondary alcohol **XV**. Oxidation of

XV with an oxidizing agent, such as manganese dioxide or by Swern oxidation, affords ketone XVI. Further reaction of ketone XVI with a second nucleophilic reagent, such as an organolithium, organocerium or Grignard reagent, in an organic solvent such as ether or THF, provides the pyridines of Formula Ia of the present invention. Reaction of Ia with an oxidizing agent, such as m-CPBA or MMPP provides the N-oxides of Formula I of the present invention.

Scheme 3



Examples 1-36

Examples 1-36 are summarized in the table below:

Example	R1	R2	R3	R4	Pyridine	n
1	CHF ₂	CHF ₂	CH ₃	CH ₃	4-Pyr	1
2	CHF ₂	CHF ₂	CH ₃	CH ₃	4-Pyr	1
3	CHF ₂	CHF ₂	CF ₃	H	4-Pyr	0
4	CHF ₂	CHF ₂	CF ₃	H	4-Pyr	1
5	CHF ₂	CHF ₂	CF ₃	CF ₃	4-Pyr	0
6	CHF ₂	CHF ₂	CF ₃	CF ₃	4-Pyr	1
7	CHF ₂	CHF ₂	CF ₃	CH ₃	4-Pyr	1
8	CHF ₂	CHF ₂	Ph	H	4-Pyr	1
9	CHF ₂	CHF ₂	Ph	CH ₃	4-Pyr	1
10	CHF ₂	CHF ₂	Ph	CF ₃	4-Pyr	1
11	CHF ₂	CHF ₂	Ph	Et	4-Pyr	1
12	CHF ₂	CHF ₂	c-Hex	H	4-Pyr	0
13	CHF ₂	CHF ₂	c-Hex	CF ₃	4-Pyr	1
14	CHF ₂	CHF ₂	4-EtPh	CH ₃	4-Pyr	1
15	CHF ₂	CHF ₂	4-EtPh	CF ₃	4-Pyr	1
16	CHF ₂	CHF ₂	4-FPh	CH ₃	4-Pyr	1
17	CHF ₂	CHF ₂	4-FPh	CF ₃	4-Pyr	1
18	CHF ₂	CHF ₂	2-(5-Br)Pyr	CF ₃	4-Pyr	1
19	CHF ₂	CHF ₂	3-(6-Br)Pyr	CF ₃	4-Pyr	1
20	CHF ₂	CHF ₂	-(CH ₂) ₃ -		4-Pyr	1
21	CHF ₂	CHF ₂	-(CH ₂) ₅ -		4-Pyr	1
22	CHF ₂	c-but	CH ₃	CH ₃	4-Pyr	1
23	CHF ₂	c-but	CH ₃	CH ₃	4-Pyr	1
24	CHF ₂	c-but	CF ₃	CF ₃	4-Pyr	0
25	CHF ₂	c-but	CF ₃	CF ₃	4-Pyr	1
26	CHF ₂	c-but	CH ₃	CH ₃	3-Pyr	0
27	CHF ₂	c-but	CH ₃	CH ₃	3-Pyr	0
28	CHF ₂	c-but	CH ₃	CH ₃	3-Pyr	1
29	CHF ₂	c-but	CH ₃	CH ₃	3-Pyr	1
30	CHF ₂	c-but	CF ₃	CF ₃	3-Pyr	1

Example	R1	R2	R3	R4	Pyridine	n
31	CHF ₂	c-but	CF ₃	CF ₃	3-Pyr	1
32	CHF ₂	c-but	CF ₃	CF ₃	2-Pyr	1
33	CHF ₂	c-pr	CH ₃	CH ₃	4-Pyr	1
34	CHF ₂	c-pr	CF ₃	CF ₃	3-Pyr	1
35	CHF ₂	c-pr	CF ₃	CF ₃	3-Pyr	1
36	CHF ₂	c-pr	CF ₃	CF ₃	3-Pyr	1


In the table above, "c-but" represents cyclobutyl, "c-pr" represents cyclopropyl, "c-pent" represents cyclopentyl, "c-Hex" represents cyclohexyl, "4-EtPh" represents 4-ethylphenyl, "4-FPh" represents 4-fluorophenyl, "Ph" represents phenyl, 5 "Pyr" represents pyridyl, "2-(5-Br)Pyr" represents 2-(5-bromo)pyridyl, and "3-(6-Br)Pyr" represents 3-(6-bromo)pyridyl.

Examples

10 All examples are mixtures of stereoisomers, either racemic mixtures (indicated as (\pm)) or racemic mixtures of diastereomers (indicated as (\pm/\pm)) unless stated otherwise. In those cases in which the stereoisomers have been separated, they are so indicated by Enantiomer 1, 2 etc. or Diastereomer 1, 2 etc.

15 Preparation of Intermediates

INTERMEDIATE 1 (\pm) -4-{2-[3,4-BIS(DIFLUOROMETHOXY)PHENYL]-2-[5-(2-FORMYL)THIAZOLYL]ETHYL}PYRIDINE



20

Step 1: 2-(1,3-Dioxan-2-yl)thiazole

A solution of 2-formylthiazole (10g, 88mmol), 1,3-propanediol (8mL) and p-TsOH (100mg) in benzene (110mL) was heated at reflux temperature for 15h with removal of water using a Dean-Stark apparatus. The mixture was cooled to room 5 temperature and washed twice with sat. aq. NaHCO₃, twice with water and concentrated. The resulting solid was crystallized from hexane to provide 2-(1,3-Dioxan-2-yl)thiazole as a tan solid (10.4g).

Step 2: (±)-3,4-Bis(difluoromethoxy)phenyl-5-[2-(1,3-dioxan-2-yl)]thiazolylcarbinol

10 To a solution of n-BuLi (37.2mL of a 2.5M solution in hexane, 93mmol) at -65°C was added a solution of 2-(1,3-dioxan-2-yl)thiazole from Step 1 (17.6g, 93mmol) in anhydrous ether (200mL) over 30min, maintaining the internal temperature at -65 to -70°C. After a further 20min, 3,4-bis(difluoromethoxy)benzaldehyde (22.1g, 93mmol) in anhydrous ether (150mL) was added over 30min. The mixture was stirred at 15 -70°C for 1h and then sat. aq. NH₄Cl (200mL) was added. The mixture was allowed to warm to room temperature and then partitioned with ether and water. The organic layer was dried (MgSO₄) and concentrated. Flash chromatography of the residue (silica gel; ethyl acetate/hexane 2:1) provided (±)-3,4-Bis(difluoromethoxy)phenyl-5-[2-(1,3-dioxan-2-yl)]thiazolylcarbinol as a yellow syrup (18.4g).

20

Step 3: (±)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1,3-dioxan-2-yl)]thiazolyl}ethyl}pyridine

25 To a solution of pyridine (10.7mL, 132mmol) in toluene (125mL) at 0°C was slowly added thionyl bromide (5.12mL, 66mmol) and the resulting mixture was stirred at this temperature for 10min. To this mixture was slowly added, over 10min, a solution of (±)-3,4-bis(difluoromethoxy)phenyl-5-[2-(1,3-dioxan-2-yl)]thiazolylcarbinol from Step 2 (18 g, 44mmol) in toluene (75mL). The mixture was stirred at 0°C for 45min and then the solids that were formed were allowed to settle. The supernatant was filtered through a pad of silica gel pre-wetted with ethyl acetate. The solids were washed with 30 ethyl acetate and filtered as well. The combined filtrates were concentrated at a bath temperature <40°C to provide the crude bromide that was used immediately.

35 To a solution of ethyl 4-pyridylacetate (26.9mL, 176mmol) in THF (250mL) and HMPA (30.6mL, 176mmol) at 0°C was added sodium bis(trimethylsilyl)amide (176mL of a 1M solution in THF, 176mmol). The resulting mixture was stirred for 45min and then a THF (140mL) solution of the bromide prepared

above was added over 20min and then stirred for 15h at 25°C. The stirred mixture was poured into sat. NH₄Cl (500mL) and extracted twice with ethyl acetate. The combined organics were washed successively with water (3X), brine, dried (MgSO₄) and concentrated to give a thick oil. This material was dissolved in a mixture of

5 THF/MeOH/1N NaOH (2:1:1, 1L) and the mixture was heated at reflux for 1h. The volatiles were removed on the rotovap, water (250mL) was added, and then 1N HCl was slowly added, bringing the pH to approximately 5. The mixture was extracted three times with ethyl acetate and the combined organics were washed with water (3X), dried (MgSO₄) and concentrated. Flash chromatography of the residue (silica gel; ethyl


10 acetate/ethanol 95:5) provided (±)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1,3-dioxan-2-yl))thiazolyl]ethyl}pyridine as a yellow syrup (15.2 g).

Step 4: (±)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-formyl)thiazolyl]ethyl}pyridine

15 A mixture of (±)-4-{2-[3,4-bis(difluoromethoxy)phenyl]-2-[5-(2-(1,3-dioxan-2-yl))thiazolyl]ethyl}pyridine from Step 3 (15g, 31mmol) and 2N HCl (150mL) in THF (200mL) was heated at reflux for 20h. The mixture was cooled to room temperature, diluted with water (500mL) and then the pH was adjusted to ~8 by the addition of 2.5N NaOH. The mixture was extracted with ether (3X) and the combined organics were

20 washed with water (2X), brine, dried (MgSO₄) and concentrated. Flash chromatography of the residue (silica gel; ethyl acetate) provided the (±)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-formyl)thiazolyl]ethyl}pyridine as an amber syrup (10.1g).

25 **THIAZOLE 1**
2-{1-METHYL-1-[(2-TRIMETHYLSILYLTHOXY)METHOXY]ETHYL}THIAZOLE



Step 1: 2-[(1-Hydroxy-1-methyl)ethyl]thiazole

To a solution of thiazole (5g, 58.8mmol) in anhydrous ether at -78°C was slowly added over 5min *n*-BuLi (40.4mL of a 1.65M solution in hexane, 64.2mmol). The resulting mixture was stirred for 20min and then acetone (5.6mL, 76.4mmol) was slowly

added. After 25min, the mixture was poured into 25% aq. NH₄OAc and the resulting mixture was extracted with ethyl acetate (5X). The combined organics were washed with brine, dried (MgSO₄) and concentrated. The residual oil (8.9g) was used as such in the next reaction.


5

Step 2: 2-{1-Methyl-1-[(2-trimethylsilylethoxy)methoxy]ethyl}thiazole

To a solution of the alcohol 2-[(1-Hydroxy-1-methyl)ethyl]thiazole from Step 1 (8.9g, 59mmol) and Hunig's base (26mL, 148mmol) in dichloromethane (75mL) at room temperature was added 2-(trimethylsilyl)ethoxymethyl chloride (12.5mL, 10.8mmol). The resulting solution was stirred at room temperature for 1h, at 50°C for 3.5h and finally at room temperature for 15h. The mixture was poured into 25% aq. NH₄OAc (200mL) and the resulting mixture was extracted with ethyl acetate (3X). The combined organics were washed with brine, dried (MgSO₄) and concentrated. Flash chromatography of the residue (silica gel; hexane/ethyl acetate 9:1) provided the 2-{1-Methyl-1-[(2-trimethylsilylethoxy)methoxy]ethyl}thiazole product as a yellow liquid (9.6g).

THIAZOLE 2

2-{1-TRIFLUOROMETHYL-1-[(2-TRIMETHYLSILYLETHOXY)METHOXY]-2,2,2-TRIFLUOROETHYL}THIAZOLE



Step 1: 2-[(1-Hydroxy-1-trifluoromethyl)-2,2,2-trifluoroethyl]thiazole

To a solution of *n*-BuLi (425mL of a 1.3M solution in hexane, 552mmol) in anhydrous ether (400mL) at -78°C was slowly added over 45min a solution of thiazole (42.7g, 502mmol) in anhydrous ether (400mL). The resulting mixture was stirred for 15min and then hexafluoroacetone was bubbled into the mixture for 30min with the bath temperature maintained between -60 to -70°C. The mixture was allowed to warm to room temperature and then poured into 25% aq. NH₄OAc. The resulting mixture was extracted with ether and then the aqueous phase was acidified to ~pH 4 with conc. HCl. The aqueous phase was extracted with ether (2X). The combined organics were washed with brine, dried (Na₂SO₄) and concentrated at <40°C. The residual liquid was distilled


at ~10 mm/Hg and the fractions distilling from 50 to 100°C was collected. The 2-[(1-Hydroxy-1-trifluoromethyl)-2,2,2-trifluoroethyl]thiazole compound (93g) was obtained as a liquid and used as such in the next reaction.

5 Step 2: 2-{1-Trifluoromethyl-1-[(2-trimethylsilylethoxy)methoxy]-2,2,2-trifluoroethyl}thiazole

To a solution of the alcohol from Step 1 (93g, 382mmol) and Hunig's base (133mL, 764mmol) in dichloromethane (1.2L) at 0°C was added 2-(trimethylsilyl)ethoxymethyl chloride (88mL, 497mmol) over 15min. The resulting 10 solution was stirred at room temperature for 15h. The mixture diluted with ether (1L) and then was poured into 25% aq. NH₄OAc (500mL). The phases were separated and the aqueous phase was extracted with ether. The combined organics were washed with brine, dried (Na₂SO₄) and concentrated. Flash chromatography of the residue (silica gel; hexane/ethyl acetate 95:5 to 9:1) provided 2-{1-Trifluoromethyl-1-[(2-trimethylsilylethoxy)methoxy]-2,2,2-trifluoroethyl}thiazole as a yellow liquid (99g).

THIAZOLE 3

2-{1-TRIFLUOROMETHYL-1-[(2-TRIMETHYLSILYLETHOXY)METHOXY]ETHYL}THIAZOLE



Step 1: 2-[(1-Hydroxy-1-trifluoromethyl)ethyl]thiazole

To a solution of n-BuLi (107mL of a 1.2 M solution in hexane, 129mmol) in anhydrous ether (100mL) at -78 °C was slowly added a solution of thiazole (10 g, 117mmol) in anhydrous ether (100mL). The resulting mixture was stirred for 20min and 25 then 1,1,1-trifluoroacetone (12.5mL, 140mmol) was added over 5min. The mixture was stirred for 1 h at -78 °C and then allowed to warm for 15min. Sat. aq. NH₄Cl was added and the phases were separated. The aqueous phase was acidified to ~pH 1 with 6N HCl and was extracted with ether. The combined organics were washed with brine, dried (Na₂SO₄) and concentrated. The residual liquid (12g) was used as such in the next 30 reaction.


Step 2: 2-{1-Trifluoromethyl-1-[(2-trimethylsilylethoxy)methoxy]ethyl}thiazole

To a solution of the alcohol 2-[(1-Hydroxy-1-trifluoromethyl)ethyl]thiazole from Step 1 (3g, 15.2mmol) in DMF (75mL) at 0°C was added sodium hydride (170mg, 16.7mmol) in two portions. The mixture was stirred at 5 0°C for 15min, at room temperature for 15min and then 2-(trimethylsilyl)ethoxymethyl chloride (2.7mL, 15.2mmol) was added over 5min. The resulting solution was stirred at room temperature for 1h and then cooled to 0°C. 25% aq. NH₄OAc was added and the mixture was diluted with ether (300mL). The phases were separated and the organic phase was washed with water (4X). The combined aqueous were re-extracted with ether. 10 The combined organics were washed with brine, dried (Na₂SO₄) and concentrated. Flash chromatography of the residue (silica gel; hexane/ethyl acetate 85:15 to 4:1) provided 2-{1-Trifluoromethyl-1-[(2-trimethylsilylethoxy)methoxy]ethyl}thiazole as a yellow liquid (3.4g).

15

THIAZOLE 4

2-{1-[(2-TRIMETHYLSILYLETHOXY)METHOXY]CYCLOBUTYL}THIAZOLE

Step 1: 2-[(1-Hydroxy)cyclobutyl]thiazole

To a solution of *n*-BuLi (36mL of a 2.5M solution in hexane, 90mmol) in 20 anhydrous ether (100mL) at -78°C was slowly added a solution of thiazole (6.35g, 74.6mmol) in anhydrous ether (60mL). The resulting mixture was stirred for 1h and then cyclobutanone (10.4g, 148mmol) in ether (20mL) was added over 5min. The mixture was stirred for 2h at -78°C and then sat. aq. NH₄Cl was added and the phases were separated. The aqueous phase was extracted with ethyl acetate (3X) and the combined organics were washed with water, brine, dried (MgSO₄) and concentrated. Flash 25 chromatography of the residue (silica gel; hexane/ethyl acetate 4:1 to 7:3) provided 2-[(1-Hydroxy)cyclobutyl]thiazole (5 g).


Step 2: 2-{1-[(2-Trimethylsilylethoxy)methoxy]cyclobutyl}thiazole

30 To a solution of the alcohol 2-[(1-Hydroxy)cyclobutyl]thiazole from Step 1 (5g, 32mmol) and Hunig's base (10.4mL, 60mmol) in dichloromethane (100mL) at 0°C

5 was added 2-(trimethylsilyl)ethoxymethyl chloride (6.5mL, 36.7mmol). The resulting solution was stirred at 0°C for 1h, was heated at reflux temperature for 3.5h and finally was stirred at room temperature for 15h. Sat. aq. NH₄Cl was added and the resulting mixture was extracted with dichloromethane (3X). The combined organics were washed with water, brine, dried (MgSO₄) and concentrated. Flash chromatography of the residue (silica gel; dichloromethane to dichloromethane/ethyl acetate 95:5) provided 2-{1-[(2-Trimethylsilylethoxy)methoxy]cyclobutyl}thiazole (2g).

THIAZOLE 5

10 2-[1-[(2-TRIMETHYLSILYLETHOXY)METHOXY]CYCLOHEXYL]THIAZOLE



Step 1: 2-[(1-Hydroxy)cyclohexyl]thiazole


To a solution of *n*-BuLi (22mL of a 2.5M solution in hexane, 55mmol) in anhydrous ether (60mL) at -78°C was slowly added a solution of thiazole (3.94g, 15 46mmol) in anhydrous ether (30mL). The resulting mixture was stirred for 1h and then cyclohexanone (9.6mL, 93mmol) in ether (25mL) was added over 5min. The mixture was stirred for 2.5h at -78°C and then sat. aq. NH₄Cl was added and the phases were separated. The aqueous phase was extracted with ethyl acetate (3X) and the combined organics were washed with water, brine, dried (MgSO₄) and concentrated. Flash chromatography of the residue (silica gel; hexane/ethyl acetate 4:1 to 7:3) provided the 2-[(1-Hydroxy)cyclohexyl]thiazole compound (5.8g).

Step 2: 2-{1-[(2-Trimethylsilyl)ethoxy]methoxy}cyclohexyl}thiazole

To a solution of the alcohol 2-[(1-Hydroxy)cyclohexyl]thiazole from Step 1 (5.8g, 32mmol) and Hunig's base (14mL, 67mmol) in dichloromethane (100mL) at 0°C was added 2-(trimethylsilyl)ethoxymethyl chloride (6.5mL, 36.7mmol). The resulting solution was stirred at 0°C for 15min, was heated at reflux temperature for 15h and then cooled to room temperature. Sat. aq. NH₄Cl was added and the resulting mixture was extracted with dichloromethane (3X). The combined organics were washed with water, brine, dried (MgSO₄) and concentrated. Flash chromatography of the residue (silica gel;

hexane/ethyl acetate 7:3) provided 2-{1-[*(2*-Trimethylsilyl)ethoxy]methoxy}cyclohexyl}thiazole (8g).

5 ALDEHYDE 1
3-CYCLOPROPYLOXY-4-DIFLUOROMETHOXYBENZALDEHYDE



Step 1: 3-(2-Chloro)ethoxy-4-difluoromethoxybenzaldehyde

A mixture of 3-hydroxy-4-difluoromethoxybenzaldehyde (77 g, 409mmol), 1-bromo-2-chloroethane (176 g, 1.23 mol) and Cs_2CO_3 (146 g, 449mmol) in 10 DMF (2 L) was stirred at 70 °C for 3 h and at 55 °C for 15h. The mixture was cooled to room temperature and partitioned between ethyl acetate (1 L) and water (2 L). The aqueous layer was extracted with ethyl acetate (2X) and the combined organics were washed with water, dried (Na_2SO_4) and concentrated. Flash chromatography of the residue (silica gel; hexane/ethyl acetate 4:1 to 7:3) provided the 3-(2-Chloro)ethoxy-4-difluoromethoxybenzaldehyde compound (87 g).

Step 2: 3-(2-Chloro)ethoxy-4-difluoromethoxy-1-(triisopropylsilyloxy)methylbenzene

To a solution of the aldehyde 3-(2-Chloro)ethoxy-4-difluoromethoxybenzaldehyde from Step 1 (87g, 347mmol) in THF (1L) and MeOH (200mL) at 0°C was added NaBH₄ (15.7g, 416mmol) in 4 portions over 20min. The resulting mixture was stirred at room temperature for 3 h, re-cooled to 0°C, and then sat. aq. NH₄Cl (50mL) was carefully added over 10min. The mixture was diluted with ethyl acetate (500mL). The mixture was partitioned between 25% aq. NH₄OAc (1L) and ethyl acetate (1L) and the aqueous layer was extracted with ethyl acetate (2X). The combined organics were washed with brine, dried (Na₂SO₄) and concentrated.

The residue was dissolved in dichloromethane (1L) and 2,6-lutidine (60mL, 520mmol) and cooled in an ice bath. Triisopropylsilyl triflate (102mL, 381mmol) was slowly added and after addition was complete, the mixture was stirred at room temperature for 2h. A second aliquot of triisopropylsilyl triflate (16mL) was added and the mixture was stirred for 15h. The mixture was cooled to 0°C and sat. aq. NaHCO_3

(50mL) was added. Ether (1.5L) and 25% aq. NH₄OAc (1L) were added and the aqueous layer was extracted with ether (2X). The combined organics were washed with brine, dried (Na₂SO₄) and concentrated. Flash chromatography of the residue (silica gel; hexane/ethyl acetate 98:2 to 95:5) provided the 3-(2-Chloro)ethoxy-4-difluoromethoxy-1-(triisopropylsilyloxy)methylbenzene compound (124g).

Step 3: 3-Ethenyloxy-4-difluoromethoxy-1-(triisopropylsilyloxy)methylbenzene

A mixture of the chloride, 3-(2-Chloro)ethoxy-4-difluoromethoxy-1-(triisopropylsilyloxy)methylbenzene, from Step 2 (124g, 303mmol), 10N NaOH (300mL, 10 3.03mol) and Bu₄NHSO₄ (102g, 303mmol) in benzene (1.3L) was heated at 65°C for 4.5h. The mixture was cooled to room temperature and was partitioned with 25% aq. NH₄OAc (500mL). The aqueous phase was extracted with ether (2X) and the combined organics were washed with brine, dried (Na₂SO₄) and concentrated. The residual oil was dissolved in dichloromethane (1L) and 2,6-lutidine (53mL, 454mmol) and cooled in an 15 ice bath. Triisopropylsilyl triflate (98mL, 363mmol) was slowly added and after addition was complete, the mixture was stirred at room temperature for 3h. The mixture was cooled to 0°C and sat. aq. NaHCO₃ (50mL) was added. Ether (1.5L) and 20 25% aq. NH₄OAc (500mL) were added and the aqueous layer was extracted with ether (2X). The combined organics were washed with brine, dried (Na₂SO₄) and concentrated. Flash chromatography of the residue (silica gel; hexane/ethyl acetate 98:2 to 95:5) provided 3-Ethenyloxy-4-difluoromethoxy-1-(triisopropylsilyloxy)methylbenzene (67g).

Step 4: 3-Cyclopropyloxy-4-difluoromethoxy-1-(triisopropylsilyloxy)methylbenzene

To a solution of the alkene, 3-Ethenyloxy-4-difluoromethoxy-1-(triisopropylsilyloxy)methylbenzene, from Step 3 (67g, 179mmol) and 25 chloroiodomethane (78mL, 1.07mol) in dichloromethane (1.5L) at 5°C (ice bath) was added diethyl zinc (55mL, 537mmol) in 5mL portions over 1.2h. During the addition, the internal temperature was maintained at <20°C. After the addition was complete, the mixture was stirred for 15min and then the cooling bath was removed and stirring was 30 continued for a further 2.5h. The mixture was re-cooled to 5°C (ice bath) and MeOH (2mL) was added over 15min, followed by the addition of water (30mL) over 15min and finally, the addition of 6N HCl (5mL). The mixture was partitioned between ether (1L) and water (500mL). The aqueous layer was extracted with ether (500mL) and the combined organics were washed with brine, dried (Na₂SO₄) and concentrated. Flash

chromatography of the residue (silica gel; hexane/ethyl acetate 98:2 to 95:5) provided 3-Cyclopropyloxy-4-difluoromethoxy-1-(triisopropylsilyloxy)methylbenzene (71g).


Step 5: 3-Cyclopropyloxy-4-difluoromethoxybenzyl alcohol

5 To a solution of the silyl ether, 3-Cyclopropyloxy-4-difluoromethoxy-1-(triisopropylsilyloxy)methylbenzene, from Step 4 (70g, 179mmol) in THF (700mL) at room temperature was added TBAF (215mL of a 1M solution in THF, 215mmol) and the resulting mixture was stirred for 17h. The mixture was partitioned between 25% aq. NH₄OAc (500mL) and ethyl acetate (1L) and the aqueous layer was extracted with ethyl acetate (2X). The combined organics were washed with brine, dried (Na₂SO₄) and concentrated. Flash chromatography of the residue (silica gel; hexane/ethyl acetate 3:2 to 1:1) provided the 3-Cyclopropyloxy-4-difluoromethoxybenzyl alcohol compound (41g).

Step 6: 3-Cyclopropyloxy-4-difluoromethoxybenzaldehyde

15 To a solution of the 3-Cyclopropyloxy-4-difluoromethoxybenzyl alcohol from Step 5 (41g, 179mmol) in dichloromethane (1.2 L) was added MnO₂ (220g, 2.15mol) in four portions over 2 days. When TLC indicated the reaction was complete, the mixture was diluted with ethyl acetate and filtered through Celite® (available from Aldrich Chemical Company, Inc., Milwaukee, Wisconsin), washing extensively with a 20 succession of ethyl acetate, dichloromethane, EtOH and toluene. The combined filtrates were concentrated. Flash chromatography of the residue (silica gel; hexane/ethyl acetate 3:1 to 7:3) provided the 3-Cyclopropyloxy-4-difluoromethoxybenzaldehyde compound (31g).

EXAMPLE 1



(±)-4-{2-[3,4-BIS(DIFLUOROMETHOXY)PHENYL]-2-[5-(2-(1-HYDROXY-1-METHYL)ETHYL]THIAZOLYL]ETHYL}PYRIDINE N-OXIDE

5

Example 1 was prepared by the following procedure:

Step 1: (±)-3,4-Bis(difluoromethoxy)phenyl-5-{2-(1-methyl-1-[(2-trimethylsilyl)ethoxy]methoxyethyl}thiazolylcarbinol

To a solution of *n*-BuLi (5.6mL of a 2.5M solution in hexane, 14mmol) in anhydrous ether (50mL) at -78°C was added a solution of Thiazole 1 (3.8g, 14mmol) in anhydrous ether (30mL). After 70min, a solution of 3,4-bis(difluoromethoxy)benzaldehyde (2.8g, 11.7mmol) in anhydrous ether (20mL) was added. The resulting mixture was stirred at -78°C for 2.5h and then sat. aq. NH₄Cl was added. The mixture was allowed to warm to room temperature and then partitioned with ethyl acetate and water. The aqueous phase was extracted with ethyl acetate (3X) and the combined organics were washed with water, brine, dried (MgSO₄) and concentrated. Flash chromatography of the residue (silica gel; hexane/ethyl acetate 4:1 to 7:3) provided the (±)-3,4-Bis(difluoromethoxy)phenyl-5-{2-(1-methyl-1-[(2-trimethylsilyl)ethoxy]methoxyethyl}thiazolylcarbinol product (3.85g).

10

Step 2: (±)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-methyl-1-[(2-trimethylsilyl)ethoxy]methoxyethyl)thiazolyl]ethyl}pyridine

To a solution of Hunig's base (1.7mL, 9.8mmol) in toluene (8mL) at 0°C was slowly added thionyl chloride (0.35mL, 4.8mmol) and the resulting mixture was stirred at this temperature for 5min. To this mixture was slowly added a solution of (±)-

3,4-bis(difluoromethoxy)phenyl-5-{2-(1-methyl-1-[(2-trimethylsilylethoxy)methoxy]ethyl}thiazolylcarbinol from Step 1 (1.6g, 3.2mmol) in toluene (10mL). The mixture was stirred at 0°C for 45min and then mixture was filtered through a pad of silica gel pre-wetted with ether, eluting with ether/hexane (4:1). The 5 filtrate was concentrated to provide the crude chloride that was used immediately.

To a solution of ethyl 4-pyridylacetate (2.12g, 12.8mmol) in THF (20mL) and HMPA (2.2mL, 12.6mmol) at room temperature was added sodium bis(trimethylsilyl)amide (12.7mL of a 1M solution in THF, 12.7mmol). The resulting mixture was stirred for 30min and then a THF (10mL) solution of the crude chloride 10 prepared above was added and then stirred for 15h at 25°C. Sat. aq. NH₄Cl was added, the layers were separated and the aqueous phase was extracted with ethyl acetate (3X). The combined organics were washed successively with water (3X), brine, dried (MgSO₄) and concentrated to give a thick oil.

This material was dissolved in a mixture of THF/MeOH/water (2:2:1, 15 20mL), LiOH (1.5g) was added and the mixture was heated at reflux for 1.5h. 1N HCl was slowly added, bringing the pH to approximately 6. The mixture was extracted three times with ethyl acetate and the combined organics were washed with water, brine, dried (MgSO₄) and concentrated. Flash chromatography of the residue (silica gel; ethyl acetate/hexane 4:1) provided the (±)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-methyl-1-[(2-trimethylsilylethoxy)methoxy]ethyl)thiazolyl]ethyl}pyridine product as an 20 oil (745mg).

Step 3: (±)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-hydroxy-1-methyl)ethyl)thiazolyl]ethyl}pyridine

25 To a solution of the protected alcohol from Step 2 (722mg, 1.23mmol) in dichloromethane (20mL) was added TFA (3.8mL, 49.3mmol) and the mixture was stirred at 0°C for 2.5h. Sat. aq. NH₄OAc was added and the mixture was extracted with ethyl acetate (3X). The combined organics were washed with water, brine, dried (MgSO₄) and concentrated. Flash chromatography of the residue (silica gel; ethyl acetate) provided the 30 (±)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-hydroxy-1-methyl)ethyl)thiazolyl]ethyl}pyridine as an oil (394mg).


Step 4: (±)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-hydroxy-1-methyl)ethyl)thiazolyl]ethyl}pyridine N-oxide

A mixture of the pyridine from Step 3 (192mg, 0.42mmol) and MMPP (209mg, 0.42mmol) in dichloromethane (12mL) and MeOH (1mL) was stirred at room temperature for 22h. The mixture was filtered through Celite® and the filtrate was concentrated. Chromatography of the residue (silica gel; dichloromethane/EtOH 4:1) 5 provided the title (\pm)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-hydroxy-1-methyl)ethyl)thiazolyl]ethyl}pyridine *N*-oxide compound as a colorless foam (112mg).

¹HNMR (400MHz, acetone-d₆): δ 1.51 (s, 6H), 3.45 (m, 2H), 4.75 (t, 1H), 4.95 (br s, 1H), 6.95 (t, 1H), 6.96 (t, 1H), 7.19 (d, 2H), 7.30 (dd, 2H), 7.38 (s, 1H), 7.48 (s, 1H), 7.94 (d, 2H).

10

EXAMPLE 2



CHIRAL 4-{2-[3,4-BIS(DIFLUOROMETHOXY)PHENYL]-2-[5-[2-(1-HYDROXY-1-METHYL)ETHYL]THIAZOLYL]ETHYL}PYRIDINE *N*-OXIDE

15

Example 2 was prepared by the following procedure:

Step 1: (\pm)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-hydroxy)ethyl)thiazolyl]ethyl}pyridine

To a solution of Intermediate 1 (5.87g, 13.8mmol) in dichloromethane 20 (170mL) at 0°C was added MeMgCl (20mL of a 3M solution in THF, 60mmol) in three portions over 1h. After a further 20min, sat. aq. NH₄Cl was added and the mixture was extracted with ethyl acetate (3X). The combined organics were washed with water, brine, dried (MgSO₄) and concentrated. Flash chromatography of the residue (silica gel; acetone/dichloromethane 3:2) provided (\pm)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-hydroxy)ethyl)thiazolyl]ethyl}pyridine as an oil (5.11g).

Step 2: (±)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-acetyl)thiazolyl]ethyl}pyridine

A mixture of the alcohol, (±)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-acetyl)thiazolyl]ethyl}pyridine, from Step 1 (5.07g, 11.5mmol) and MnO₂ (11 g, 126.5mmol) in dichloromethane (100mL) was stirred at room temperature for 48h. The mixture was filtered through Celite®, washing with dichloromethane, and the filtrate was concentrated. Flash chromatography of the residue (silica gel; acetone/dichloromethane 1:3) provided (±)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-acetyl)thiazolyl]ethyl}pyridine as an oil (4.87g).

10

Step 3: Resolution of (±)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-acetyl)thiazolyl]ethyl}pyridine

A solution of (±)-4-{2-[3,4-bis(difluoromethoxy)phenyl]-2-[5-(2-acetyl)thiazolyl]ethyl}pyridine (Step 2; 4.87g) in EtOH/hexane (21mL, 2:3) was injected (3 X 7mL) onto a Chiralpak® AD (available from Chiral Technologies, Inc., Exton, Pennsylvania) preparative (5cm X 50cm) HPLC column (eluting with hexane/ethanol 3:1 at 55mL/min with UV detection at 270nm). The enantiomers were separated with the faster eluting enantiomer having a retention time of ~38min (Enantiomer 1) and the slower eluting enantiomer (Enantiomer 2) having a retention time of ~66min. The eluants were concentrated to provide the enantiomers as brown gums: Enantiomer 1 (2.2g) and Enantiomer 2 (2.3g).

Step 4: Chiral 4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-hydroxy-1-methyl)ethyl)thiazolyl]ethyl}pyridine

A mixture of CeCl₃ (288mg, 1.17mmol; dried at 140°C for 15h) in THF (12mL) was heated at reflux for 3h and then cooled to 0°C. MeMgCl (1.7mL of a 3M solution in THF, 5.1mmol) was added and the mixture was stirred for 2h. A solution of Enantiomer 2 (Step 3, 400mg, 0.91mmol) in toluene (4mL) was added dropwise and the mixture was stirred for 1h. Sat. aq. NH₄Cl was added and the mixture was extracted with ethyl acetate (3X). The combined organics were washed with water, brine, dried (MgSO₄) and concentrated. Flash chromatography of the residue (silica gel; acetone/dichloromethane 1:1) provided the Chiral 4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-hydroxy-1-methyl)ethyl)thiazolyl]ethyl}pyridine product as an oil (383mg).

35


Step 5: Chiral 4-[2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-hydroxy-1-methyl)ethyl)thiazolyl]ethyl]pyridine N-oxide

5 A mixture of the pyridine from Step 4 (383mg, 0.84mmol) and MMPP (415mg, 0.89mmol) in dichloromethane (25mL) and MeOH (25mL) was stirred at room temperature for 48h. The mixture was filtered through Celite® and the filtrate was washed with sat. aq. NaHCO₃, water, brine, dried (MgSO₄) and concentrated. Chromatography of the residue (silica gel; ethyl acetate/EtOH 65:35) provided the title Chiral 4-[2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-hydroxy-1-methyl)ethyl)thiazolyl]ethyl]pyridine compound as a colorless foam (306mg).

10 ¹HNMR (400MHz, acetone-d₆): δ 1.51 (s, 6H), 3.45 (m, 2H), 4.75 (t, 1H), 4.95 (br s, 1H), 6.95 (t, 1H), 6.96 (t, 1H), 7.19 (d, 2H), 7.30 (dd, 2H), 7.38 (s, 1H), 7.48 (s, 1H), 7.94 (d, 2H).

15

EXAMPLE 3



(±/±)-4-[2-[3,4-BIS(DIFLUOROMETHOXY)PHENYL]-2-[5-(2-(1-HYDROXY-2,2,2-TRIFLUORO)ETHYL)THIAZOLYL]ETHYL]PYRIDINE


20

Example 3 was prepared by the following procedure. To a mixture of Intermediate 1 (1.24g, 2.9mmol) and trimethyl(trifluoromethyl)silane (0.9mL, 6.5mmol) in THF (15mL) at 0°C was added TBAF (0.13mL of a 1M solution in THF, 0.13mmol). After 1h, 1M HCl (10mL) was added and the mixture was stirred for 1.5h at room temperature. The mixture was basified with sat. aq. Na₂CO₃ and then extracted with ethyl acetate (3X). The combined organics were dried (MgSO₄) and concentrated.

Chromatography of the residue (silica gel; acetone/toluene 3:7 to 1:1) provided the title compound as a colorless foam (892mg).

5 ^1H NMR (400MHz, acetone- d_6): δ 3.51 (m, 2H), 4.90 (t, 1H), 5.43 (m, 1H), 6.64 (br s, 1H), 6.94 (t, 1H), 6.95 (t, 1H), 7.12-7.41 (m, 5H), 7.66 (d, 1H), 8.38 (m, 2H).

EXAMPLE 4




10 (\pm) -4-{2-[3,4-BIS(DIFLUOROMETHOXY)PHENYL]-2-[5-(2-(1-HYDROXY-2,2,2-TRIFLUORO)ETHYL)THIAZOLYL]ETHYL}PYRIDINE *N*-OXIDE

15 Example 4 was prepared by the following procedure. A mixture of the pyridine from Example 3 (166mg, 0.34mmol) and MMPP (99mg, 0.35mmol) in dichloromethane (12mL) and MeOH (3mL) was stirred at room temperature for 48h. An additional 25mg of MMPP was added and the mixture was heated at reflux temperature for 5h. The mixture was filtered through Celite®, 1N NaOH was added and the mixture was extracted with ethyl acetate (3X). The combined organics were dried (MgSO_4) and concentrated. Chromatography of the residue (silica gel; dichloromethane/MeOH 9:1) provided the title compound as a colorless foam (106mg).

20 ^1H NMR (400MHz, acetone- d_6): δ 3.51 (m, 2H), 4.87 (t, 1H), 5.43 (m, 1H), 6.89 (br s, 1H), 6.96 (t, 2H), 7.22 (d, 2H), 7.33 (m, 2H), 7.41 (d, 1H), 7.68 (m, 1H), 7.96 (d, 2H).

EXAMPLE 5



(±)-4-[2-[3,4-BIS(DIFLUOROMETHOXY)PHENYL]-2-{5-[2-(1-HYDROXY-1-
5 TRIFLUOROMETHYL-2,2,2-


TRIFLUORO)ETHYL]THIAZOLYL}ETHYL]PYRIDINE

Example 5 was prepared by following the procedures described in
Example 1, Steps 1 to 3, but substituting Thiazole 2 for Thiazole 1. Flash
chromatography silica gel; toluene/acetone 7:3 to 3:2 provided the title product as a foam
10 (208mg).

¹HNMR (400MHz, acetone-d₆): δ 3.55 (m, 2H), 4.96 (t, 1H), 6.94 (t, 1H),
6.96 (t, 1H), 7.20 (d, 2H), 7.30 (d, 1H), 7.36 (d, 1H), 7.42 (s, 1H), 7.81 (s, 1H), 8.20 (br s,
1H), 8.38 (d, 2H).

15

EXAMPLE 6



(±)-4-{2-[3,4-BIS(DIFLUOROMETHOXY)PHENYL]-2-{5-[2-(1-HYDROXY-1-TRIFLUOROMETHYL-2,2,2-


5 TRIFLUORO)ETHYL]THIAZOLYL}ETHYL}PYRIDINE N-OXIDE

Example 6 was prepared by following the procedures described in Example 1, Step 4, but substituting Example 5 for the pyridine from Example 1, Step 3. The title compound (flash chromatography silica gel; dichloromethane/MeOH 9:1) was obtained as a foam (100mg).

10 ¹HNMR (400MHz, acetone-d₆): δ 3.55 (m, 2H), 4.91 (t, 1H), 6.95 (t, 2H), 7.22 (d, 2H), 7.32 (d, 1H), 7.37 (d, 1H), 7.42 (s, 1H), 7.80 (s, 1H), 7.96 (d, 2H), 8.50(br s, 1H).

15

EXAMPLE 7



(\pm/\pm)-4-{2-[3,4-BIS(DIFLUOROMETHOXY)PHENYL]-2-[5-[2-(1-HYDROXY-1-TRIFLUOROMETHYL)ETHYL]THIAZOLYL]ETHYL}PYRIDINE N-OXIDE

5

Example 7 was prepared by the following procedure:

Step 1: (\pm/\pm)-3,4-Bis(difluoromethoxy)phenyl-5-{2-(1-trifluoromethyl-1-[(2-trimethylsilylethoxy)methoxyethyl]thiazolylcarbinol}

To a solution of Thiazole 3 (3.4g, 10.4mmol) in anhydrous THF (30mL) at 10 -78°C was added *n*-BuLi (8.7mL of a 1.2M solution in hexane, 10.4mmol) over 10min. After 30min, a solution of 3,4-bis(difluoromethoxy)benzaldehyde (2.7g, 10.4mmol) in anhydrous THF (30mL) was added via cannula. The mixture was stirred at -78°C for 1h, the cooling bath was removed and then, after 15min, sat. aq. NH_4Cl was added. The mixture was partitioned with ethyl acetate and water. The aqueous phase was extracted 15 with ethyl acetate (3X) and the combined organics were washed with brine, dried (Na_2SO_4) and concentrated. Flash chromatography of the residue (silica gel; hexane/ethyl acetate 7:3 to 3:2) provided (\pm/\pm)-3,4-Bis(difluoromethoxy)phenyl-5-{2-(1-trifluoromethyl-1-[(2-trimethylsilylethoxy)methoxyethyl]thiazolylcarbinol (5.66g).

20 Step 2: (\pm/\pm)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-trifluoromethyl-1-[(2-trimethylsilylethoxy)methoxyethyl]thiazolyl]ethyl]pyridine

To a solution of pyridine (1.6mL, 19.8mmol) in toluene (50mL) at 0°C was slowly added thionyl bromide (1mL, 12.9mmol) and the resulting mixture was stirred at this temperature for 5min. To this mixture was slowly added a solution of the alcohol, 25 (\pm/\pm)-3,4-Bis(difluoromethoxy)phenyl-5-{2-(1-trifluoromethyl-1-[(2-trimethylsilylethoxy)methoxyethyl]thiazolylcarbinol, from Step 1 (5.6g, 9.9mmol) in

toluene (50mL). The mixture was stirred at room temperature for 1h and then concentrated to provide the crude bromide that was used immediately.

To a solution of ethyl 4-pyridylacetate (6.5g, 39.6mmol) in THF (200mL) and HMPA (6.8mL, 39.6mmol) at room temperature was added potassium 5 bis(trimethylsilyl)amide (79mL of a 0.5M solution in toluene, 39.6mmol). The resulting mixture was stirred for 30min and then a THF (50mL) solution of the crude bromide prepared above was added and then stirred for 2h at 25°C. 25% aq. NH₄OAc and ethyl acetate were added, the layers were separated and the aqueous phase was extracted with ethyl acetate. The combined organics were washed with brine, dried (Na₂SO₄) and 10 concentrated to give a thick oil. This material was dissolved in a mixture of THF/MeOH/water (3:1:1, 300mL), 2N NaOH (60mL) was added and the mixture was heated at 65°C for 3h. After cooling to room temperature, 6N HCl was slowly added, bringing the pH to approximately 6. The mixture was concentrated and partitioned with ethyl acetate and 25% aq. NH₄OAc. The aqueous phase was extracted with ethyl acetate 15 and the combined organics were washed with brine, dried (Na₂SO₄) and concentrated. Flash chromatography of the residue (silica gel; ethyl acetate/hexane 3:2 to 4:1) provided (±/±)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-trifluoromethyl-1-[(2-trimethylsilylethoxy)methoxy]ethyl)thiazolyl]ethyl}pyridine as an oil (4g).

20 Step 3: (±/±)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-hydroxy-1-trifluoromethyl)ethyl)thiazolyl]ethyl}pyridine

To a solution of the protected alcohol, (±/±)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-trifluoromethyl-1-[(2-trimethylsilylethoxy)methoxy]ethyl)thiazolyl]ethyl}pyridine, from Step 2 (200mg, 25 0.31mmol) in dichloromethane (3mL) was added TFA (trifluoroacetic acid) (0.5mL) and the mixture was stirred at room temperature for 15min. The mixture was concentrated and then partitioned with sat. aq. NH₄OAc and ethyl acetate. The aqueous phase was extracted with ethyl acetate and the combined organics were washed with brine, dried (Na₂SO₄) and concentrated. Flash chromatography of the residue (silica gel; 30 dichloromethane/EtOH 9:1) provided (±/±)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-hydroxy-1-trifluoromethyl)ethyl)thiazolyl]ethyl}pyridine as an oil (115mg).


Step 4: (\pm/\pm)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-hydroxy-1-trifluoromethyl)ethyl)thiazolyl]ethyl}pyridine *N*-oxide

A mixture of the (\pm/\pm)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-hydroxy-1-trifluoromethyl)ethyl)thiazolyl]ethyl}pyridine from Step 3 (115mg, 0.23mmol) and MMPP (222mg, 0.45mmol) in dichloromethane (5mL) and MeOH (0.5mL) was heated at 50°C for 30min and then additional MMPP (0.5eq) and MeOH (0.25mL) was added. The mixture was stirred at 50°C for 30min and then at room temperature for 15h. The mixture was concentrated. Flash chromatography of the residue (silica gel; dichloromethane/MeOH/10% NH₄OH 8:1:1) provided the title compound as a colorless foam (117mg).

¹HNMR (500MHz, acetone-d₆): δ 1.78 (s, 3H), 3.50 (m, 2H), 4.84 (m, 1H), 6.5 (d, 1H), 6.95 (t, 1H), 6.96 (t, 1H), 7.21 (d, 2H), 7.33 (m, 2H), 7.40 (d, 1H), 7.66 (d, 1H), 7.95 (d, 2H).

15

EXAMPLE 8



(\pm/\pm)-4-{2-[3,4-BIS(DIFLUOROMETHOXY)PHENYL]-2-[5-(2-PHENYLMETHANOL)THIAZOLYL]ETHYL}PYRIDINE *N*-OXIDE

20

Example 8 was prepared by the following procedure:

Step 1: (±/±)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-phenylmethanol)thiazolyl]ethyl}pyridine


To a solution of Intermediate 1 (1.48 g, 3.5mmol) in dichloromethane (38mL) at 0°C was added dropwise PhMgCl (5.2mL of a 2M solution in THF, 10.4mmol). After 30min, a second aliquot of PhMgCl (2mL) was added. After a further 30min, sat. aq. NH₄Cl was added and the mixture was extracted with ethyl acetate (3X). The combined organics were washed with water, brine, dried (MgSO₄) and concentrated. Chromatography of the residue (silica gel; dichloromethane/acetone 7:3 to 3:2) provided (±/±)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-phenylmethanol)thiazolyl]ethyl}pyridine as a colorless oil (1.32g).

Step 2: (±/±)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-phenylmethanol)thiazolyl]ethyl}pyridine N-oxide

Following the procedures described in Example 1, Step 4, but substituting the (±/±)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-phenylmethanol)thiazolyl]ethyl}pyridine from Step 1 (65mg, 0.13mmol) for the pyridine from Example 1, Step 3, the (±/±)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-phenylmethanol)thiazolyl]ethyl}pyridine N-oxide title compound (chromatography silica gel; dichloromethane/EtOH 7:3) was obtained as an oil (33mg).

¹HNMR (500MHz, acetone-d₆): δ 3.43 (m, 2H), 4.76 (m, 1H), 5.71 (br s, 1H), 5.95 (s, 1H), 6.94 (t, 2H), 7.17 (br s, 2H), 7.24-7.49 (m, 4H), 7.93 (m, 2H).

EXAMPLE 9



(\pm/\pm)-4-{2-[3,4-BIS(DIFLUOROMETHOXY)PHENYL]-2-[5-(2-(1-HYDROXY-1-PHENYL)ETHYL)THIAZOLYL]ETHYL}PYRIDINE N-OXIDE

5

Example 9 was prepared by the following procedure:

Step 1: (\pm)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-benzoyl)thiazolyl]ethyl}pyridine

To a solution of oxalyl chloride (0.45mL, 5.2mmol) in dichloromethane (20mL) at -78°C was added DMSO (0.74mL, 10mmol). After 5min, a solution of the alcohol (1.30g, 2.58mmol) from Step 1 of Example 8 in dichloromethane (20mL) was added and the mixture was stirred for 2h. Triethylamine (3mL, 22mmol) was added and after 1.5h, the mixture was warmed to room temperature. Water was added and the mixture was extracted with ethyl acetate (3X). The combined organics were washed with water, brine, dried (MgSO_4) and concentrated. Flash chromatography of the residue (silica gel; hexane/ethyl acetate 35:65 to 3:7) provided (\pm)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-benzoyl)thiazolyl]ethyl}pyridine as a colorless oil (869mg).

20 Step 2: (\pm/\pm)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-hydroxy-1-phenyl)ethyl)thiazolyl]ethyl}pyridine

To a solution of the ketone, (\pm)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-benzoyl)thiazolyl]ethyl}pyridine, from the present Step 1 (413mg, 0.82mmol) in dichloromethane (20mL) at -78°C , was added dropwise MeMgBr (0.8mL of a 3M

solution in ether, 2.4mmol). After 15min, a second aliquot of MeMgBr (0.2mL) was added. After a further 30min, 25% aq. NH₄OAc was added and the mixture was extracted with dichloromethane (3X). The combined organics were washed with brine, dried (MgSO₄) and concentrated. Flash chromatography of the residue (silica gel; ethyl acetate/hexane 9:1 to 1:0) provided (\pm/\pm)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-hydroxy-1-phenyl)ethyl)thiazolyl]ethyl}pyridine as a colorless oil (332mg).


Step 3: (\pm/\pm)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-hydroxy-1-phenyl)ethyl)thiazolyl]ethyl}pyridine *N*-oxide

Following the procedures described in Example 1, Step 4, but substituting the (\pm/\pm)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-hydroxy-1-phenyl)ethyl)thiazolyl]ethyl}pyridine from Step 2 (293mg, 0.57mmol) for the pyridine from Example 1, Step 3, the title (\pm/\pm)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-hydroxy-1-phenyl)ethyl)thiazolyl]ethyl}pyridine *N*-oxide compound (chromatography silica gel; dichloromethane/MeOH 9:1) was obtained as a white foam (163mg).

¹HNMR (400MHz, acetone-d₆): δ 1.92 and 1.93 (s each, 3H), 3.42 (m, 2H), 4.72 (m, 1H), 5.70 (br s, 1H), 6.94 (app t, 2H), 7.11-7.37 (m, 8H), 7.49 (d, 1H), 7.57 (m, 2H), 7.92 (m, 2H).

20

EXAMPLE 10




(\pm/\pm)-4-{2-[3,4-BIS(DIFLUOROMETHOXY)PHENYL]-2-[5-(2-(1-HYDROXY-1-PHENYL-2,2,2-TRIFLUORO)ETHYL)THIAZOLYL]ETHYL}PYRIDINE *N*-OXIDE

Example 10 was prepared by following the procedures described in Examples 3 and 4, but substituting the ketone from Example 9, Step 1 (450mg, 1.06mmol) for Intermediate 1. The title compound was obtained (chromatography silica gel; dichloromethane/MeOH 9:1) as a yellow foam (80mg).

¹HNMR (400MHz, acetone-d₆): δ 3.49 (m, 2H), 4.83 (m, 1H), 6.94 (app t, 2H), 7.17-7.35 (m, 4H), 7.40 (m, 4H), 7.69-7.78 (m, 3H), 7.92 (d, 2H).

10

EXAMPLE 11




(±/±)-4-(2-[3,4-BIS(DIFLUOROMETHOXY)PHENYL]-2-[5-(2-(1-HYDROXY-1-PHENYL)PROPYL)THIAZOLYL]ETHYL)PYRIDINE N-OXIDE

15

Example 11 was prepared by following the procedures described in Example 9, Steps 2 and 3, but substituting EtMgBr (1M in THF) for MeMgBr. The title compound was obtained (chromatography silica gel; dichloromethane/MeOH 9:1) as a foam (80mg).

¹HNMR (400MHz, acetone-d₆): δ 0.79 (t, 3H), 2.34 (q, 2H), 3.40 (m, 2H), 4.70 (m, 1H), 5.36 (m, 1H), 6.93 (app t, 2H), 7.11-7.35 (m, 8H), 7.51 (d, 1H), 7.61 (m, 2H), 7.91 (m, 2H).

EXAMPLE 12




$$(\pm/\pm)\text{-}4\text{-}\{2\text{-}\{3,4\text{-BIS(DIFLUOROMETHOXY)PHENYL}\}\text{-}2\text{-}\{5\text{-}\{2\text{-CYCLOHEXYLMETHANOL\}}\text{THIAZOLYL}\}JETHYL\}\text{PYRIDINE}$$

5

Example 12 was prepared by the following procedure. To a solution of Intermediate 1 (740mg, 1.74mmol) in dichloromethane (20mL) at 0°C was added dropwise cyclohexylmagnesium chloride (2.6mL of a 2M solution in ether, 5.2mmol). After 1h, sat. aq. NH₄Cl was added and the mixture was extracted with ethyl acetate (3X). The combined organics were washed with water, brine, dried (MgSO₄) and concentrated. Flash chromatography of the residue (silica gel; dichloromethane/MeOH 96:4) provided the title compound as a colorless oil (462mg).

¹HNMR (400MHz, acetone-d₆): δ 1.15 (m, 5H), 1.5-1.8 (m, 6H), 3.45 (m, 2H), 4.60 (m, 1H), 4.80 (m, 1H), 5.01 (m, 1H), 6.94 (app t, 2H), 7.16-7.50 (m, 6H), 8.35 (m, 2H).

EXAMPLE 13



(\pm/\pm)-4-{2-[3,4-BIS(DIFLUOROMETHOXY)PHENYL]-2-[5-(2-(1-HYDROXY-1-CYCLOHEXYL-2,2,2-TRIFLUOROMETHYL)ETHYL)THIAZOLYL]ETHYL}PYRIDINE *N*-OXIDE

Example 13 was prepared by the following procedure:

Step 1: (\pm)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(cyclohexylcarbonyl)thiazolyl]ethyl}pyridine


Following the procedures described in Example 9, Step 1, but substituting the alcohol from Example 12 (446mg, 0.87mmol) for the alcohol from Example 8, Step 1, (\pm)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(cyclohexylcarbonyl)thiazolyl]ethyl}pyridine (chromatography silica gel; toluene/acetone 4:1 to 3:1) was obtained as an oil (314mg).

Step 2: (\pm/\pm)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-hydroxy-1-cyclohexyl-2,2,2-trifluoromethyl)ethyl)thiazolyl]ethyl}pyridine *N*-oxide

Following the procedures described in Examples 3 and 4, but substituting the ketone from the present Step 1 (295mg, 0.58mmol) for Intermediate 1, the title compound was obtained (chromatography silica gel; dichloromethane/MeOH 9:1) as a foam (97mg).

^1H NMR (400MHz, acetone- d_6): δ 1.1-1.4 (m, 6H), 1.55-1.95 (m, 4H), 2.3 (m, 1H), 3.50 (m, 2H), 4.82 (m, 1H), 6.06 (m, 1H), 6.96 (app t, 2H), 7.19 (m, 2H), 7.32 (m, 2H), 7.39 (s, 1H), 7.64 (d, 1H), 7.94 (d, 2H).

EXAMPLE 14



5 (\pm/\pm) -4-{2-[3,4-BIS(DIFLUOROMETHOXY)PHENYL]-2-[5-(2-(1-HYDROXY-1-(4-ETHYL)PHENYL)ETHYL)THIAZOLYL]ETHYL}PYRIDINE N-OXIDE

Example 14 was prepared by the following procedure:

Step 1: (\pm/\pm) -4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(4-ethylphenyl)methanol)thiazolyl]ethyl}pyridine

To a solution of Intermediate 1 (426mg, 1mmol) in dichloromethane (10mL) at 0°C was added dropwise 4-ethylphenylmagnesium bromide (7.2mL of a 0.42M solution in THF, 3mmol). After 30min, a second aliquot of 4-ethylphenylmagnesium bromide (2.5mL) was added. After a further 1h, the mixture was warmed to room temperature and sat. aq. NH₄Cl was added. The mixture was extracted with ether (2X). The combined organics were washed with brine (2X), dried (MgSO₄) and concentrated. Chromatography of the residue (silica gel; dichloromethane/acetone 7:3) provided (\pm/\pm) -4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(4-ethylphenyl)methanol)thiazolyl]ethyl}pyridine as a yellow syrup (290mg).

20

Step 2: (±)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(4-ethyl)benzoyl)thiazolyl]ethyl}pyridine

A mixture of the alcohol from Step 1 (280mg, 0.53mmol), MnO₂ (274mg, 3.2mmol) and Celite® (500mg) in dichloromethane (15mL) was stirred at room 5 temperature for 24h. A second aliquot of MnO₂ (137mg) was added and stirring continued for a further 3h. The mixture was filtered through Celite®, washing with dichloromethane, and the filtrate was concentrated. Flash chromatography of the residue (silica gel; acetone/dichloromethane 3:7) provided (±)-4-{2-[3,4-
10 Bis(difluoromethoxy)phenyl]-2-[5-(2-(4-ethyl)benzoyl)thiazolyl]ethyl}pyridine as a yellow syrup (236mg).

Step 3: (±/±)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-hydroxy-1-(4-ethyl)phenyl)ethyl)thiazolyl]ethyl}pyridine


To a solution of the ketone from Step 2 (236mg, 0.45mmol) in 15 dichloromethane (5mL) at 0°C was added dropwise MeMgCl (0.52mL of a 3M solution in THF, 1.56mmol). After 15min, sat. aq. NH₄Cl and ethyl acetate were added. The aqueous phase was extracted with ethyl acetate (3X). The combined organics were dried (MgSO₄) and concentrated. Flash chromatography of the residue (silica gel; dichloromethane/acetone 7:3) provided (±/±)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-hydroxy-1-(4-ethyl)phenyl)ethyl)thiazolyl]ethyl}pyridine as a yellow syrup 20 (228mg).

Step 4: (±/±)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-hydroxy-1-(4-ethyl)phenyl)ethyl)thiazolyl]ethyl}pyridine N-oxide

25 Following the procedures described in Example 1, Step 4, but substituting the pyridine from the present Step 3 (198mg, 0.36mmol) for the pyridine from Example 1, Step 3, the title compound (chromatography silica gel; dichloromethane/MeOH 92.5:7.5) was obtained as a white foam (169mg).

30 ¹HNMR (400MHz, acetone-d₆): δ 1.16 (m, 3H), 1.91 and 1.92 (s each, 3H), 2.57 (m, 2H), 3.42 (m, 2H), 4.73 (m, 1H), 5.54 (m, 1H), 6.94 (app t, 2H), 7.11-7.18 (m, 4H), 7.24-7.36 (m, 3H), 7.45-7.50 (m, 3H), 7.91 (m, 2H).

EXAMPLE 15



5


(\pm/\pm)-4-{2-[3,4-BIS(DIFLUOROMETHOXY)PHENYL]-2-[5-(2-(1-HYDROXY-1-(4-ETHYL)PHENYL-2,2,2-TRIFLUORO)ETHYL)THIAZOLYL]ETHYL}PYRIDINE N-OXIDE

Example 15 was prepared by following the procedures described in Examples 3 and 4, but substituting the ketone from Example 14, Step 2 (210mg, 0.4mmol) for Intermediate 1. The title compound was obtained (chromatography silica gel; dichloromethane/MeOH 9:1) as a white foam (117mg).

10 ^1H NMR (400MHz, acetone- d_6): δ 1.20 (m, 3H), 2.63 (m, 2H), 3.48 (m, 2H), 4.82 (m, 1H), 6.92 (app t, 2H), 7.10-7.35 (m, 7H), 7.40 (s, 1H), 7.61-7.74 (m, 3H), 7.93 (d, 2H).

15

EXAMPLE 16




(\pm/\pm)-4-{2-[3,4-BIS(DIFLUOROMETHOXY)PHENYL]-2-[5-(2-(1-HYDROXY-1-(4-FLUORO)PHENYL)ETHYL)THIAZOLYL]ETHYL}PYRIDINE *N*-OXIDE

Example 16 was prepared by following the procedures described in Examples 14, but substituting 4-fluorophenylmagnesium bromide for 4-ethylphenylmagnesium bromide. The title compound was obtained (chromatography 10 silica gel; dichloromethane/MeOH 9:1) as a white foam (100mg).

¹H NMR (400 MHz, acetone-d₆): δ 1.91 (m, 3H), 3.46 (m, 2H), 4.73 (m, 1H), 5.78 (m, 1H), 6.92 (app t, 2H), 7.05 (m, 2H), 7.17 (m, 2H), 7.25-7.38 (m, 3H), 7.51 (d, 1H), 7.60 (m, 2H), 7.92 (m, 2H).

15

EXAMPLE 17



(\pm/\pm)-4-[2-[3,4-BIS(DIFLUOROMETHOXY)PHENYL]-2-[5-(2-(1-HYDROXY-1-(4-FLUORO)PHENYL-2,2,2-TRIFLUORO)ETHYL)THIAZOLYL]ETHYL}PYRIDINE *N*-OXIDE

Example 17 was prepared by the following procedure:

10 Step 1: (±)-4-[2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(4-fluoro)benzoyl)thiazolyl]ethyl]pyridine

Following the procedures described in Examples 14, Steps 1 and 2, but substituting 4-fluorophenylmagnesium bromide for 4-ethylphenylmagnesium bromide, (\pm) -4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(4-fluoro)benzoyl)thiazolyl]ethyl}pyridine was obtained (chromatography silica gel; 15 hexane/ethyl acetate 2:3 to 3:7) as a white foam (443mg).


Step 2: (\pm/\pm)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-hydroxy-1-(4-fluoro)phenyl-2,2,2-trifluoroethyl)thiazolyl]ethyl}pyridine N-oxide

Following the procedures described in Examples 3 and 4, but substituting the ketone from the present Step 1 (300mg, 0.58mmol) for Intermediate 1, the title compound was obtained (chromatography silica gel; dichloromethane/EtOH 9:1) as a foam (100mg).

¹HNMR (400MHz, acetone-d₆): δ 3.49 (m, 2H), 4.83 (m, 1H), 6.94 (app t, 2H), 7.12-7.23 (m, 4H), 7.30 (m, 2H), 7.40 (m, 2H), 7.71 (m, 1H), 7.82 (m, 2H), 7.93 (d, 2H).

5

EXAMPLE 18



(±/±)-4-{2-[3,4-BIS(DIFLUOROMETHOXY)PHENYL]-2-[5-(2-(1-HYDROXY-1-(5-BROMOPYRIDIN-2-YL)-2,2,2-

10 TRIFLUORO)ETHYL)THIAZOLYL]ETHYL}PYRIDINE N-OXIDE

Example 18 was prepared by the following procedure:

Step 1: (±/±)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(5-bromopyridin-2-yl)methanol)thiazolyl]ethyl}pyridine

15 To a solution/suspension of 2,5-dibromopyridine (427mg, 1.8mmol) in toluene (20mL) at -78°C was slowly added *n*-BuLi (0.72mL of a 2.3M solution in hexane, 1.65mmol) and the resulting mixture was stirred at this temperature for 3.5h. To this mixture was added a solution of Intermediate 1 (639mg, 1.5mmol) in toluene (5mL). After 75min, sat. aq. NH₄Cl was added and the mixture was warmed to room
20 temperature. The mixture was extracted with ethyl acetate (2X) and the combined organics were washed with water (3X), dried (MgSO₄), concentrated and used as such in the subsequent reaction below.

Step 2: (±)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(5-bromopyridin-2-yl)keto)thiazolyl]ethyl}pyridine


A mixture of the alcohol from the present Step 1, MnO₂ (1.96g, 22.5mmol) and Celite® (3g) in dichloromethane (30mL) was stirred at room temperature 5 for 24h. The mixture was filtered through Celite®, washing with dichloromethane, and the filtrate was concentrated. Flash chromatography of the residue (silica gel; ethyl acetate) provided (±)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(5-bromopyridin-2-yl)keto)thiazolyl]ethyl}pyridine as an oil (247mg).

10 Step 3: (±/±)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-hydroxy-1-(5-bromopyridin-2-yl)-2,2,2-trifluoro)ethyl)thiazolyl]ethyl}pyridine N-oxide

Following the procedures described in Examples 3 and 4, but substituting the ketone from the present Step 2 (235mg, 0.40mmol) for Intermediate 1, the title compound was obtained (chromatography silica gel; dichloromethane/EtOH 9:1) as a 15 yellow foam (32mg).

¹HNMR (400MHz, acetone-d₆): δ 3.40-3.57 (m, 2H), 4.84 (m, 1H), 6.94 (app t, 2H), 7.16-7.34 (m, 5H), 7.39 (s, 1H), 7.76 (d, 1H), 7.91-7.95 (m, 2H), 8.13 (m, 1H), 8.21-8.25 (m, 1H), 8.77 (s, 1H).

EXAMPLE 19



(±/±)-4-(2-[3,4-BIS(DIFLUOROMETHOXY)PHENYL]-2-[5-(2-(1-HYDROXY-1-(6-BROMOPYRIDIN-3-YL)-2,2,2-TRIFLUORO)ETHYL]THIAZOLYL]ETHYL)PYRIDINE N-OXIDE

Example 19 was prepared by the following procedure:

Step 1: (±/±)-4-(2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(6-bromopyridin-3-yl)methanol)thiazolyl]ethyl)pyridine

10 To a solution/suspension of 2,5-dibromopyridine (1.66 g, 7mmol) in ether (50mL) at -78°C was slowly added *n*-BuLi (2.6mL of a 2.3M solution in hexane, 6mmol) and the resulting mixture was stirred at this temperature for 1.5h. To this mixture was added a solution of Intermediate 1 (2.13g, 5mmol) in ether (20mL). The mixture was stirred at -78°C for 2h and then warmed to 0°C. After 3.5h, sat. aq. NH₄Cl (75mL) was added and the mixture was warmed to room temperature. The mixture was partitioned with ethyl acetate and water and the organic phase was dried (MgSO₄), concentrated and used as such in the subsequent reaction.


20 Step 2: (±/±)-4-(2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-hydroxy-1-(6-bromopyridin-3-yl)-2,2,2-trifluoro)ethyl]thiazolyl]ethyl)pyridine N-oxide

Following the procedures described in Example 18, Steps 2 and 3, but substituting the alcohol obtained from the present Step 1 for the alcohol from Example

18, Step 1, the title compound was obtained (chromatography silica gel; dichloromethane/MeOH 9:1) as a white foam (374mg).

1 ^1H NMR (400MHz, acetone- d_6): δ 3.41-3.56 (m, 2H), 4.87 (m, 1H), 6.95
 5 (app t, 2H), 7.20 (m, 2H), 7.28-7.35 (m, 2H), 7.40 (s, 1H), 7.69 (m, 1H), 7.75 (s, 1H),
 7.82 (br s, 1H), 7.92 (m, 2H), 8.12 (m, 1H), 8.76 (s, 1H).

EXAMPLE 20




10 (\pm) -4-{2-[3,4-BIS(DIFLUOROMETHOXY)PHENYL]-2-[5-[2-(1-HYDROXY)CYCLOBUTYL]THIAZOLYL]ETHYL}PYRIDINE N-OXIDE

15 Example 20 was prepared by following the procedures described in Example 1, but substituting Thiazole 4 for Thiazole 1. The title compound was obtained (chromatography silica gel; dichloromethane/MeOH 92:8) as a white solid (164mg, m.p. 151-153°C).

20 ^1H NMR (400MHz, acetone- d_6): δ 1.89 (m, 2H), 2.22 (m, 2H), 2.55 (m, 2H), 3.47 (m, 2H), 4.78 (m, 1H), 5.42 (br s, 1H), 6.95 (app t, 1H), 6.96 (t, 1H), 7.21 (m, 2H), 7.30 (m, 2H), 7.38 (s, 1H), 7.53 (s, 1H), 7.95 (d, 2H).

EXAMPLE 21




(\pm)-4-{2-[3,4-BIS(DIFLUOROMETHOXY)PHENYL]-2-[5-[2-(1-HYDROXY)CYCLOHEXYL]THIAZOLYL]ETHYL}PYRIDINE N-OXIDE

5

Example 21 was prepared by following the procedures described in Example 1, but substituting Thiazole 5 for Thiazole 1. The title compound was obtained (chromatography silica gel; dichloromethane/MeOH 9:1) as a foam (144mg).

10 ^1H NMR (400MHz, acetone-d₆): δ 1.30 (m, 1H), 1.50-1.80 (m, 7H), 1.90 (m, 2H), 3.44 (m, 2H), 4.75 (m, 2H), 6.95 (app t, 2H), 7.20 (m, 2H), 7.29 (m, 2H), 7.37 (s, 1H), 7.48 (s, 1 H), 7.94 (d, 2H).

EXAMPLE 22



(±)-4-{2-[(3-CYCLOBUTYLOXY-4-DIFLUOROMETHOXY)PHENYL]-2-[5-[2-(1-HYDROXY-1-METHYL)ETHYL]THIAZOLYL]ETHYL}PYRIDINE N-OXIDE

5

Example 22 was prepared by the following procedure:

Step 1: (±)-(3-Cyclobutyloxy-4-difluoromethoxy)phenyl-5-{2-(1-methyl-1-[(2-trimethylsilylethoxy)methoxy]ethyl)thiazolyl}carbinol

To a solution of Thiazole 1 (1.0g, 3.66mmol) in anhydrous ether (10mL) at 10 -78°C was added *n*-BuLi (2.3mL of a 1.6M solution in hexane, 3.66mmol). After 40min, a solution of 3-cyclobutyloxy-4-difluoromethoxybenzaldehyde (886mg, 3.66mmol) in anhydrous ether (2mL) was added. The mixture was stirred at -78°C for 35min and then 25% aq. NH₄OAc was added. The mixture was allowed to warm to room temperature and then partitioned with ethyl acetate and water. The aqueous phase was extracted with 15 ethyl acetate and the combined organics were washed with brine, dried (MgSO₄) and concentrated. Flash chromatography of the residue (silica gel; hexane/ethyl acetate 65:35) provided (±)-(3-Cyclobutyloxy-4-difluoromethoxy)phenyl-5-{2-(1-methyl-1-[(2-trimethylsilylethoxy)methoxy]ethyl)thiazolyl}carbinol as an amber oil (1.2g).

20 Step 2: (±)-4-{2-[(3-Cyclobutyloxy-4-difluoromethoxy)phenyl]-2-[5-(2-(1-methyl-1-[(2-trimethylsilylethoxy)methoxy]ethyl)thiazolyl]ethyl}pyridine

To a solution of pyridine (0.47mL, 5.82mmol) in toluene (2mL) at room 25 temperature was slowly added thionyl chloride (0.20mL, 2.79mmol) and the resulting mixture was stirred for 10min. To this mixture was slowly added a solution of the alcohol from the present Step 1 (1.2g, 2.33mmol) in toluene (2mL). The mixture was

stirred for 25min to give a precipitate. The liquid was decanted and the residual solid washed with toluene. The combined organics were concentrated to provide the crude chloride as an amber oil that was used immediately.

To a solution of ethyl 4-pyridylacetate (1.15g, 7mmol) in THF (10mL) and 5 HMPA (1.21mL, 7mmol) at room temperature was added potassium bis(trimethylsilyl)amide (14mL of a 0.5M solution in toluene, 7mmol). The resulting mixture was stirred for 30min and then a THF (5mL) solution of the crude chloride prepared above was added and then stirred for 17h at 25°C. Then, 25% aq. NH₄OAc was added, the layers were separated and the aqueous phase was extracted with ethyl acetate. 10 The combined organics were washed successively with brine, dried (MgSO₄) and concentrated to give a thick orange oil. This material was dissolved in a mixture of THF/MeOH/water (3:1:1, 25mL), LiOH (557mg) was added and the mixture was heated at 70°C for 1h. After cooling to room temperature, 1N HCl (25mL) was slowly added. The mixture was extracted three times with ethyl acetate and the combined organics were 15 washed with brine, dried (MgSO₄) and concentrated. Flash chromatography of the residue (silica gel; ethyl acetate/hexane 3:1) provided (±)-4-{2-[(3-Cyclobutyloxy-4-difluoromethoxy)phenyl]-2-[5-(2-(1-methyl-1-[(2-trimethylsilylethoxy)methoxy]ethyl)thiazolyl]ethyl}pyridine as an orange oil (892mg).

20 **Step 3: (±)-4-{2-[(3-Cyclobutyloxy-4-difluoromethoxy)phenyl]-2-[5-(2-(1-methyl-1-[(2-trimethylsilylethoxy)methoxy]ethyl)thiazolyl]ethyl}pyridine N-oxide**


A mixture of the (±)-4-{2-[(3-Cyclobutyloxy-4-difluoromethoxy)phenyl]-2-[5-(2-(1-methyl-1-[(2-trimethylsilylethoxy)methoxy]ethyl)thiazolyl]ethyl}pyridine from Step 2 (892mg, 1.51mmol) and MMPP (747mg, 1.51mmol) in dichloromethane (9mL) 25 and MeOH (1mL) was stirred at room temperature for 16h. The mixture was partitioned with ethyl acetate and sat. aq. NaHCO₃. The aqueous phase was extracted with ethyl acetate and the combined organics were washed with brine, dried (MgSO₄) and concentrated. Flash chromatography of the residue (silica gel; dichloromethane/MeOH 9:1) provided (±)-4-{2-[(3-Cyclobutyloxy-4-difluoromethoxy)phenyl]-2-[5-(2-(1-methyl- 30 1-[(2-trimethylsilylethoxy)methoxy]ethyl)thiazolyl]ethyl}pyridine N-oxide as a pale yellow foam (782mg).

Step 4: (±)-4-{2-[(3-Cyclobutyloxy-4-difluoromethoxy)phenyl]-2-[5-[2-(1-hydroxy-1-methyl)ethyl]thiazolyl]ethyl}pyridine N-oxide

To a solution of the protected alcohol, (±)-4-{2-[(3-Cyclobutyloxy-4-difluoromethoxy)phenyl]-2-[5-(2-(1-methyl-1-[(2-trimethylsilylethoxy)methoxy]ethyl)thiazolyl]ethyl}pyridine N-oxide, from Step 3 (782mg, 1.29mmol) in dichloromethane (10mL) at 0 °C was added TFA (1mL) and the mixture was stirred at 0°C for 20min. The mixture was warmed to room temperature and then stirred for an additional 5h. 25% aq. NH₄OAc was added and the mixture was extracted with ethyl acetate. The organics were washed with brine, dried (MgSO₄) and concentrated. Flash chromatography of the residue (silica gel; dichloromethane/MeOH 9:1) provided the title product as an off white solid (520mg).

¹HNMR (400MHz, acetone-d₆): δ 1.51 (s, 6H), 1.67 (m, 1H), 1.81 (m, 1H), 2.0-2.2 (m, 2H), 2.35-2.50 (m, 2H), 3.42 (m, 2H), 4.66 (t, 1H), 4.74 (m, 1H), 4.91 (br s, 1H), 6.84 (t, 1H), 6.92 (m, 1H), 6.97 (m, 1H), 7.08 (d, 1H), 7.18 (d, 2H), 7.48 (s, 1H), 7.97 (d, 2H).

EXAMPLE 23



20 CHIRAL 4-{2-[(3-CYCLOBUTYLOXY-4-DIFLUOROMETHOXY)PHENYL]-2-[5-[2-(1-HYDROXY-1-METHYL)ETHYL]THIAZOLYL]ETHYL}PYRIDINE N-OXIDE

Example 23 was prepared by the following procedure:

Step 1: Resolution of (\pm)-4-{2-[(3-Cyclobutyloxy-4-difluoromethoxy)phenyl]-2-[5-(2-(1-methyl-1-[(2-trimethylsilylethoxy)methoxy]ethyl)thiazolyl]ethyl}pyridine

A solution of (\pm)-4-{2-[(3-Cyclobutyloxy-4-difluoromethoxy)phenyl]-2-[5-(2-(1-methyl-1-[(2-trimethylsilylethoxy)methoxy]ethyl)thiazolyl]ethyl}pyridine (Example 22, Step 2; 2.3g) in isopropanol/hexane (30mL, 1:4) was injected (5 X 6mL) onto a Chiralpak® AD preparative (5cm X 50cm) HPLC column (eluting with hexane/isopropanol 96:4 at 75mL/min with UV detection at 280nm). The enantiomers were separated with the faster eluting enantiomer having a retention time of ~46min (Enantiomer 1) and the slower eluting enantiomer (Enantiomer 2) having a retention time of ~51min. The eluants were concentrated to provide the enantiomers as off-white gums: Enantiomer 1 (761mg) and Enantiomer 2 (547mg).


Step 2: Chiral 4-{2-[(3-Cyclobutyloxy-4-difluoromethoxy)phenyl]-2-[5-[2-(1-hydroxy-1-methyl)ethyl]thiazolyl]ethyl}pyridine N-oxide

Following the procedures described in Example 22, Steps 3 and 4, but substituting chiral pyridine from the present Step 1 (Enantiomer 1; 750mg, 1.27mmol) for the racemic pyridine from Example 22, Step 2, the title compound was obtained (chromatography silica gel; chloroform/EtOH 9:1 to 4:1) as a white foam (473mg).

¹HNMR (500MHz, acetone-d₆): δ 1.52 (s, 6H), 1.68 (m, 1H), 1.81 (m, 1H), 2.0-2.2 (m, 2H), 2.38-2.50 (m, 2H), 3.36-3.47 (m, 2H), 4.66 (t, 1H), 4.75 (m, 1H), 4.90 (br s, 1H), 6.83 (t, 1H), 6.92 (m, 1H), 6.96 (m, 1H), 7.08 (d, 1H), 7.17 (d, 2H), 7.47 (s, 1H), 7.97 (d, 2H).

25

EXAMPLE 24




5 (±)-4-{2-[(3-CYCLOBUTYLOXY-4-DIFLUOROMETHOXY)PHENYL]-2-{5-[2-(1-HYDROXY-1-TRIFLUOROMETHYL-2,2,2-
10 TRIFLUORO)ETHYL]THIAZOLYL}ETHYL}PYRIDINE

Example 24 was prepared by following the procedures described in Example 5, but substituting 3-cyclobutyloxy-4-difluoromethoxybenzaldehyde for 3,4-bis(difluoromethoxy)benzaldehyde, the title compound (chromatography silica gel; toluene/acetone 7:3) was obtained as a foam (277mg).

¹HNMR (500MHz, acetone-d₆): δ 1.66 (m, 1H), 1.80 (m, 1H), 2.0-2.2 (m, 2H), 2.30-2.50 (m, 2H), 3.40-3.53 (m, 2H), 4.70 (m, 1H), 4.78 (t, 1H), 6.83 (t, 1H), 6.94 (m, 2H), 7.06 (d, 1H), 7.16 (d, 2H), 7.68 (s, 1H), 8.37 (br s, 2H).

EXAMPLE 25



(±)-4-{2-[(3-CYCLOBUTYLOXY-4-DIFLUOROMETHOXY)PHENYL]-2-{5-[2-(1-HYDROXY-1-TRIFLUOROMETHYL-2,2,2-TRIFLUORO)ETHYL]THIAZOLYL}ETHYL}PYRIDINE N-OXIDE

5


Example 25 was prepared by following the procedures described in Example 6, but substituting Example 24 (203mg, 0.35mmol) for Example 5. The title compound (chromatography silica gel; dichloromethane/MeOH 93:7) was obtained as a white foam (100mg).

10

¹HNMR (400MHz, acetone-d₆): δ 1.67 (m, 1H), 1.81 (m, 1H), 2.0-2.2 (m, 2H), 2.30-2.50 (m, 2H), 3.45-3.59 (m, 2H), 4.75 (m, 1H), 4.81 (t, 1H), 6.85 (t, 1H), 6.94-7.0 (m, 2H), 7.10 (d, 1H), 7.19 (d, 2H), 7.81 (s, 1H), 7.97 (br d, 2H), 8.45 (br s, 1H).

15

EXAMPLES 26 AND 27



CHIRAL 3-{2-[{(3-cyclobutyloxy)-4-difluoromethoxy]phenyl}-2-{5-[2-(1-hydroxy-1-methyl)ethyl]thiazolyl}ethyl}pyridine

5

Examples 26 and 27 were prepared by the following procedure:

Step 1: (±)-3-{2-[{(3-Cyclobutyloxy)-4-difluoromethoxy]phenyl}-2-{5-[2-(1-hydroxy-1-methyl)ethyl]thiazolyl}ethyl}pyridine

To a solution of pyridine (1.8mL, 22.2mmol) in toluene (50mL) at 0°C
 10 was slowly added thionyl chloride (0.78mL, 10.7mmol) and the resulting mixture was
 stirred at room temperature for 15min. To this mixture was slowly added a solution of
 the alcohol from Example 22, Step 1 (4.6 g, 8.9mmol), in toluene (25mL). The mixture
 was stirred for 20min to give a precipitate. The mixture was filtered and the residual
 solid washed with toluene. The combined organics were concentrated to provide the
 15 crude chloride as an amber oil that was used immediately.

To a solution of ethyl 3-pyridylacetate (4.4 g, 26.7mmol) in THF (110mL)
 and HMPA (4.6mL, 26.7mmol) at room temperature was added potassium
 bis(trimethylsilyl)amide (53.4mL of a 0.5M solution in toluene, 7mmol). The resulting
 mixture was stirred for 20min and then a THF (20mL) solution of the crude chloride
 20 prepared above was added and then stirred for 17h at 25°C. The mixture was poured into
 25% aq. NH₄OAc, the layers were separated and the aqueous phase was extracted with
 ethyl acetate (3X). The combined organics were washed successively with water (3X),
 dried (MgSO₄) and concentrated. Flash chromatography of the residue (silica gel; ethyl
 acetate/hexane 1:1 to 3:2) provided the esters as a yellow oil (2.5g).


This material (2.5g, 3.8mmol) was dissolved in a mixture of THF/MeOH/water (3:1:1, 30mL), 2N LiOH (5.7mL, 11.4mmol) was added and the mixture was heated at 70°C for 30min and then stirred at room temperature for 15h. 4N HCl (25mL) was slowly added, bringing the mixture to ~pH 5. The mixture was 5 concentrated and then extracted three times with ethyl acetate. The combined organics were washed with water (3X), dried (MgSO₄) and concentrated to give the acid (2.1g). The acid was dissolved in DMSO (10mL) and heated at 150°C for 7h and then stirred at room temperature for 15h. Water (50mL) and brine (5mL) were added and the mixture was extracted with dichloromethane (3X). The combined organics were washed with 10 water (3X), dried (MgSO₄) and concentrated. Flash chromatography of the residue (silica gel; ethyl acetate/EtOH 1:0 to 9:1) provided the title product as an oil (855mg).

Step 2: Resolution of (±)-3-{2-[(3-Cyclobutyloxy-4-difluoromethoxy)phenyl]-2-{5-[2-(1-hydroxy-1-methyl)ethyl]thiazolyl}ethyl}pyridine

15 A solution of the material from the present Step 1 (855mg) in EtOH/hexane (5mL, 2:3) was injected onto a Chiralpak® AD preparative (5cm X 50cm) HPLC column (eluting with hexane/EtOH 85:15 at 80mL/min with UV detection at 280nm). The enantiomers were separated with the faster eluting enantiomer having a retention time of ~25min (Enantiomer 1) and the slower eluting enantiomer (Enantiomer 20 2) having a retention time of ~34min. The eluants were concentrated to provide the enantiomers as white foams: Enantiomer 1 (Example 26, 400mg) and Enantiomer 2 (Example 27, 385mg).

25 ¹HNMR (500MHz, acetone-d₆) for both enantiomers: δ 1.52 (s, 6H), 1.67 (m, 1H), 1.81 (m, 1H), 2.0-2.2 (m, 2H), 2.34-2.50 (m, 2H), 3.34-3.49 (m, 2H), 4.63 (t, 1H), 4.73 (m, 1H), 4.86 (s, 1H), 6.82 (t, 1H), 6.90-6.95 (m, 2H), 7.07 (d, 1H), 7.18 (m, 1H), 7.46 (s, 1H), 7.55 (d, 1H), 8.42 (m, 1H), 8.47 (s, 1H).

EXAMPLE 28




CHIRAL 3-{2-[3-CYCLOBUTYLOXY-4-DIFLUOROMETHOXY)PHENYL]-2-{5-[2-(1-HYDROXY-1-METHYL)ETHYL]THIAZOLYL}ETHYL}PYRIDINE N-OXIDE

5

Example 28 was prepared by the following procedure. A mixture of Example 26 (Enantiomer 1; 400mg, 0.87mmol) and MMPP (430mg, 0.87mmol) in dichloromethane (9mL) and MeOH (0.9mL) was stirred at room temperature for 16h. The mixture was partitioned with dichloromethane and sat. aq. NaHCO_3 . The aqueous 10 phase was extracted with dichloromethane and the combined organics were washed with brine, dried (MgSO_4) and concentrated. Flash chromatography of the residue (silica gel; dichloromethane/EtOH 9:1 to 4:1) provided the title compound as a white foam (280mg).

^1H NMR (500MHz, acetone- d_6): δ 1.52 (s, 6H), 1.66 (m, 1H), 1.81 (m, 1H), 2.0-2.2 (m, 2H), 2.37-2.50 (m, 2H), 3.33-3.47 (m, 2H), 4.69 (t, 1H), 4.75 (m, 1H), 4.93 (br s, 1H), 6.82 (t, 1H), 6.93-7.00 (m, 2H), 7.09 (t, 2H), 7.20 (t, 1H), 7.49 (s, 1H), 7.92 (d, 1H), 8.02 (s, 1H).

EXAMPLE 29



CHIRAL 3-{2-[(3-CYCLOBUTYLOXY-4-DIFLUOROMETHOXY)PHENYL]-2-{5-[2-(1-HYDROXY-1-METHYL)ETHYL]THIAZOLYL}ETHYL}PYRIDINE N-OXIDE


5

Example 29 was prepared by following the procedures described in Example 28, but substituting Example 27 (Enantiomer 2; 385mg, 0.84mmol) for Example 26. The title compound (chromatography silica gel; dichloromethane/EtOH 9:1 to 4:1) was obtained as a white foam (310mg).

10 ^1H NMR (500MHz, acetone-d₆): δ 1.52 (s, 6H), 1.66 (m, 1H), 1.81 (m, 1H), 2.0-2.2 (m, 2H), 2.37-2.50 (m, 2H), 3.33-3.47 (m, 2H), 4.69 (t, 1H), 4.75 (m, 1H), 4.93 (br s, 1H), 6.82 (t, 1H), 6.93-7.00 (m, 2H), 7.09 (t, 2H), 7.20 (t, 1H), 7.49 (s, 1H), 7.92 (d, 1H), 8.02 (s, 1H).

15

EXAMPLES 30 AND 31



5 CHIRAL 3-{2-[(3-CYCLOBUTYLOXY-4-DIFLUOROMETHOXY)PHENYL]-2-{5-[2-(1-HYDROXY-1-TRIFLUOROMETHYL-2,2,2-TRIFLUORO)ETHYL]THIAZOLYL}ETHYL}PYRIDINE N-OXIDE

Examples 30 and 31 were prepared by the following procedure:

Step 1: (\pm)-(3-Cyclobutyloxy-4-difluoromethoxy)phenyl-5-{2-(1-trifluoromethyl-1-[(2-trimethylsilyl)ethoxy]methoxy]-2,2,2-trifluoroethyl}thiazolylcarbinol

10 To a solution *n*-BuLi (8.5mL of a 1.6M solution in hexane, 13.6mmol) in anhydrous ether (20mL) at -78°C was added a solution of Thiazole 2 (5.17g, 13.55mmol) in anhydrous ether (10mL). After 1.5h, this mixture was added to a solution of 3-cyclobutyloxy-4-difluoromethoxybenzaldehyde (2.17 g, 8.97mmol) in anhydrous ether (30mL) at -78°C. The mixture was stirred at -78°C for 2h and then sat. aq. NH₄Cl was added. The mixture was extracted with ethyl acetate and the organics were washed with brine, dried (Na₂SO₄) and concentrated. Flash chromatography of the residue (silica gel; hexane/ethyl acetate 95:5 to 7:3) provided (\pm)-(3-Cyclobutyloxy-4-difluoromethoxy)phenyl-5-{2-(1-trifluoromethyl-1-[(2-trimethylsilyl)ethoxy]methoxy]-2,2,2-trifluoroethyl}thiazolylcarbinol as a yellow oil (4.99g).

15 20 Step 2: (\pm)-3-{2-[(3-Cyclobutyloxy-4-difluoromethoxy)phenyl]-2-{5-[2-(1-hydroxy-1-trifluoromethyl-2,2,2-trifluoro)ethyl]thiazolyl}ethyl}pyridine N-oxide

To a solution of pyridine (2mL, 26.7mmol) in toluene (5mL) at 0°C was slowly added thionyl bromide (1mL, 12.9mmol) and the resulting mixture was stirred for 10min. To this mixture was slowly added a solution of the alcohol from the present Step

1 (4.99g, 8.0mmol) in toluene (15mL). The mixture was warmed to room temperature and stirred for 45min to give a precipitate. The mixture was added directly to a silica gel column and eluted with hexane/ethyl acetate (4:1) to provide the crude bromide as a pale yellow oil (3.67g) that was used immediately.

5 To a solution of ethyl 3-pyridylacetate *N*-oxide (2.4g, 13.25mmol) in THF (80mL) and HMPA (2.4mL, 13.8mmol) at 0°C was added potassium bis(trimethylsilyl)amide (27mL of a 0.5M solution in toluene, 13.5mmol). The resulting mixture was warmed to room temperature and stirred for 1.5h. The mixture was re-cooled to 0°C and then a THF (10mL) solution of the crude bromide prepared above 10 (2.97g, 4.33mmol) was added. After stirring for 17h at 25°C, the mixture was poured into sat. aq. NH₄Cl, the layers were separated and the aqueous phase was extracted with ethyl acetate. The combined organics were washed with brine, dried (Na₂SO₄) and concentrated. Flash chromatography of the residue (silica gel; dichloromethane/EtOH 98:2 to 95:5) provided the esters as a yellow oil (3.2 g).

15 This material (3.2 g, 3.7mmol) was dissolved in a mixture of THF/MeOH/water (3:1:1, 35mL), 1.7N LiOH (7mL, 11.9mmol) was added and the mixture was heated at 60°C for 5h. A second aliquot of 1.7N LiOH (7mL) was added and heating was continued for a further 4h. The mixture was cooled to room temperature and then 2N HCl (14mL) was slowly added. The mixture was concentrated and partitioned 20 between ethyl acetate and water. The aqueous phase was extracted with ethyl acetate and the combined organics were washed with brine, dried (Na₂SO₄) and concentrated to give the acid (2.64g). The acid was dissolved in DMSO (20mL) and heated at 110-130°C for 4.5h and then stirred at room temperature for 15h. Water (200mL) was added and the mixture was extracted with dichloromethane (3X). The combined organics were washed 25 with brine, dried (Na₂SO₄) and concentrated. Flash chromatography of the residue (silica gel; dichloromethane/MeOH/10% aq. NH₄OH 90:5:5) provided (±)-3-{2-[3-Cyclobutoxy-4-difluoromethoxy)phenyl]-2-{5-[2-(1-hydroxy-1-trifluoromethyl-2,2,2-trifluoro)ethyl]thiazolyl}ethyl}pyridine *N*-oxide as a white foam (1.4g).

30 Step 3: Resolution of (±)-3-{2-[3-Cyclobutoxy-4-difluoromethoxy)phenyl]-2-{5-[2-(1-hydroxy-1-trifluoromethyl-2,2,2-trifluoro)ethyl]thiazolyl}ethyl}pyridine *N*-oxide


35 A solution of the material from the present Step 2 (1.4g) in EtOH/hexane (20mL, 3:7) was injected (4 X 5mL) onto a Chiraldak® AD preparative (5cm X 50cm) HPLC column (eluting with hexane/EtOH 9:1 at 60-80mL/min with UV detection at 270nm). The enantiomers were separated with the faster eluting enantiomer having a

retention time of ~16min (Enantiomer 1, Example 30) and the slower eluting enantiomer (Enantiomer 2, Example 31) having a retention time of ~19min. The eluants were concentrated to provide the enantiomers as white foams: Enantiomer 1 (579mg) and Enantiomer 2 (132mg).

5 ^1H NMR (500MHz, acetone-d₆) for each enantiomer: δ 1.65 (m, 1H), 1.81 (m, 1H), 2.0-2.2 (m, 2H), 2.35-2.50 (m, 2H), 3.43-3.57 (m, 2H), 4.76 (m, 1H), 4.87 (t, 1H), 6.85 (t, 1H), 6.96-7.02 (m, 2H), 7.10 (t, 2H), 7.22 (t, 1H), 7.35 (s, 1H); 7.94 (d, 1H), 8.06 (s, 1H), 8.28 (br s, 1H).

10

EXAMPLE 32



15 (\pm) -2-{2-[(3-CYCLOBUTYLOXY-4-DIFLUOROMETHOXY)PHENYL]-2-{5-[2-(1-

HYDROXY-1-TRIFLUOROMETHYL-2,2,2-

TRIFLUOROETHYL)ETHYL]THIAZOLYL}ETHYL}PYRIDINE N-OXIDE

Example 32 was prepared by the following procedure:
Step 1: (\pm) -2-{2-[(3-Cyclobutyloxy-4-difluoromethoxy)phenyl]-2-{5-[2-(1-trifluoromethyl-1-[(2-trimethylsilylethoxy)methoxy]-2,2,2-trifluoroethyl]thiazolyl}ethyl}pyridine
20 To a solution of diisopropylamine (0.14mL, 1mmol) in THF (2mL) at 0°C was added *n*-BuLi (0.62mL of a 1.6M solution in hexane, 0.99mmol). After 45min, the resulting mixture was cooled to -78°C and ethyl 2-pyridylacetate (0.15mL, 0.98mmol) was added. The mixture stirred for 1h and then a THF (4mL) solution of the bromide prepared in Example 30, Step 2 (0.22 g, 0.33mmol) was added. After stirring for 17h at

25°C, the mixture was poured into 25% aq. NH₄OAc. The aqueous phase was extracted with ethyl acetate and the organics were washed with brine, dried (Na₂SO₄) and concentrated.

This material was dissolved in a mixture of THF/MeOH/water (3:1:1, 5 10mL), 1.7N LiOH (2mL, 3.4mmol) was added and the mixture was heated at 60°C for 2.5h. The mixture was cooled to room temperature and then 2N HCl (2mL) was slowly added. The mixture was concentrated and partitioned between ethyl acetate and 25% aq. NH₄OAc. The aqueous phase was extracted with ethyl acetate and the combined organics were washed with brine, dried (Na₂SO₄) and concentrated. Flash chromatography of the 10 residue (silica gel; hexane/ethyl acetate 7:3) provided the protected alcohol, (±)-2-{2-[(3-Cyclobutyloxy-4-difluoromethoxy)phenyl]-2-{5-[2-(1-trifluoromethyl-1-[(2-trimethylsilylethoxy)methoxy]-2,2,2-trifluoroethyl]thiazolyl}ethyl}pyridine, as an oil (169mg).


15 Step 2: (±)-2-{2-[(3-Cyclobutyloxy-4-difluoromethoxy)phenyl]-2-{5-[2-(1-hydroxy-1-trifluoromethyl-2,2,2-trifluoro)ethyl]thiazolyl}ethyl}pyridine
A mixture of the protected alcohol from the present Step 1 (169mg, 0.24mmol) and TBAF (2.5mL of a 1M solution in THF, 2.5mmol) in THF (3mL) was heated at 60°C for 17h. 25% aq. NH₄OAc was added, the mixture was extracted with 20 ethyl acetate and the combined organics were washed with brine, dried (Na₂SO₄) and concentrated. Flash chromatography of the residue (silica gel; hexane/ethyl acetate 1:1) provided (±)-2-{2-[(3-Cyclobutyloxy-4-difluoromethoxy)phenyl]-2-{5-[2-(1-hydroxy-1-trifluoromethyl-2,2,2-trifluoro)ethyl]thiazolyl}ethyl}pyridine as an oil (107mg).

25 Step 3: (±)-2-{2-[(3-Cyclobutyloxy-4-difluoromethoxy)phenyl]-2-{5-[2-(1-hydroxy-1-trifluoromethyl-2,2,2-trifluoro)ethyl]thiazolyl}ethyl}pyridine N-oxide
A mixture of (±)-2-{2-[(3-Cyclobutyloxy-4-difluoromethoxy)phenyl]-2-{5-[2-(1-hydroxy-1-trifluoromethyl-2,2,2-trifluoro)ethyl]thiazolyl}ethyl}pyridine from the present Step 2 (107mg, 0.19mmol) and MMPP (185mg, 0.37mmol) in 30 dichloromethane (5mL) and MeOH (0.5mL) was stirred at room temperature for 2h. A second aliquot of MMPP (185mg) was added and the mixture was stirred for 48h. The mixture was filtered through Celite® and concentrated. Flash chromatography of the residue (silica gel; dichloromethane/MeOH/10% aq. NH₄OH 95:2.5:2.5), followed by a second chromatography of the mixed fractions (silica gel; ethyl acetate/EtOH 95:5) 35 provided the title compound as a white foam (26mg).

¹HNMR (500MHz, acetone-d₆): δ 1.65 (m, 1H), 1.80 (m, 1H), 1.95-2.18 (m, 2H), 2.32-2.48 (m, 2H), 3.60 (m, 1H), 3.75 (m, 1H), 4.63 (m, 1H), 5.28 (t, 1H), 6.83 (t, 1H), 6.90-7.97 (m, 2H), 7.09 (d, 2H), 7.15 (m, 2H), 7.29 (m, 1H), 7.80 (s, 1H), 8.23 (d, 1H), 8.70 (br s, 1H).

5

EXAMPLE 33




10 (±)-4-{2-[(3-CYCLOPROPYLOXY-4-DIFLUOROMETHOXY)PHENYL]-2-{5-[2-(1-HYDROXY-1-METHYL)ETHYL]THIAZOLYL}ETHYL}PYRIDINE N-OXIDE

15 Example 33 was prepared by following the procedures described in Example 22, but substituting 3-cyclopropyloxy-4-difluoromethoxybenzaldehyde for 3-cyclobutyloxy-4-difluoromethoxybenzaldehyde. The title compound (chromatography silica gel; dichloromethane/EtOH 7:3) was obtained as a white foam (126mg).

¹HNMR (400MHz, acetone-d₆): δ 0.60-0.85 (m, 4H), 1.52 (s, 6H), 3.36-3.50 (m, 2H), 3.88 (m, 1H), 4.69 (t, 1H), 4.95 (s, 1H), 6.76 (t, 1H), 6.95 (m, 1H), 7.07 (d, 1H), 7.18 (d, 2H), 7.41 (m, 1H), 7.48 (s, 1H), 7.96 (d, 2H).

20

EXAMPLE 34



(±)-3-{2-[(3-CYCLOPROPYLOXY-4-DIFLUOROMETHOXY)PHENYL]-2-{5-[2-(1-HYDROXY-1-TRIFLUOROMETHYL-2,2,2-TRIFLUORO)ETHYL]THIAZOLYL}ETHYL}PYRIDINE N-OXIDE

5

Example 34 was prepared by the following procedure:

Step 1: (±)-(3-Cyclopropyloxy-4-difluoromethoxy)phenyl-5-{2-(1-trifluoromethyl-1-[(2-trimethylsilyl)ethoxy]methoxy]-2,2,2-trifluoroethyl}thiazolylcarbinol

10 To a solution *n*-BuLi (13mL of a 1.6M solution in hexane, 20.8mmol) in anhydrous ether (40mL) at -78°C was added a solution of Thiazole 2 (8.07 g, 21.2mmol) in anhydrous ether (25mL). After 1.5h, this mixture was added to a solution of 3-cyclopropyloxy-4-difluoromethoxybenzaldehyde (3.03g, 13.3mmol) in anhydrous ether (30mL) at -78°C. The mixture was stirred at -78°C for 1.75h and then sat. aq. NH₄Cl was added. The mixture was extracted with ethyl acetate and the organics were washed with brine, dried (Na₂SO₄) and concentrated. Flash chromatography of the residue (silica gel; hexane/ethyl acetate 9:1 to 7:3) provided the alcohol, (±)-(3-Cyclopropyloxy-4-difluoromethoxy)phenyl-5-{2-(1-trifluoromethyl-1-[(2-trimethylsilyl)ethoxy]methoxy]-2,2,2-trifluoroethyl}thiazolylcarbinol, as a yellow oil (7.05g).

15 20 Step 2: (±)-3-{2-[(3-Cyclopropyloxy-4-difluoromethoxy)phenyl]-2-{5-[2-(1-hydroxy-1-trifluoromethyl-2,2,2-trifluoro)ethyl]thiazolyl}ethyl}pyridine N-oxide

To a solution of pyridine (1.6mL, 19.8mmol) in toluene (5mL) at 0°C was slowly added thionyl bromide (0.84mL, 10.8mmol) and the resulting mixture was stirred for 5min. To this mixture was slowly added a solution of the alcohol from the present

Step 1 (4.38g, 7.2mmol) in toluene (10mL). The mixture was warmed to room temperature and stirred for 45min. The mixture was added directly to a silica gel column and eluted with hexane/ethyl acetate (95:5 to 7:3) to provide the crude bromide as a yellow oil (2.59g) that was used immediately.

5 To a suspension of ethyl 3-pyridylacetate *N*-oxide (2 g, 11.0mmol) in THF (60mL) and HMPA (2mL, 11.5mmol) at 0°C was added potassium bis(trimethylsilyl)amide (22mL of a 0.5M solution in toluene, 11.0mmol). The resulting mixture was warmed to room temperature and stirred for 1.5h. The mixture was re-cooled to 0°C and then a THF (10mL) solution of the crude bromide prepared above

10 (2.37g, 3.5mmol) was added. After stirring for 17h at 25°C, the mixture was poured into sat. aq. NH₄Cl, the layers were separated and the aqueous phase was extracted with ethyl acetate. The combined organics were washed with brine, dried (Na₂SO₄) and concentrated. Flash chromatography of the residue (silica gel; dichloromethane/EtOH 98:2 to 95:5) provided the esters as a white foam (2.35g).

15 This material (2.35g, 3.5mmol) was dissolved in a mixture of THF/MeOH/water (3:1:1, 33mL). Next, 1.7N LiOH (6.5mL, 11.1mmol) was added and the resulting mixture was heated at 60°C for 2.5h. The mixture was cooled to room temperature and then 2N HCl (6.5mL) was slowly added. The mixture was concentrated and partitioned between ethyl acetate and water. The aqueous phase was extracted with


20 ethyl acetate and the combined organics were washed with brine, dried (Na₂SO₄) and concentrated to give a yellow solid (2.4g). This material was dissolved in DMSO (30mL) and heated at 130°C for 2h. Water (300mL) was added and the mixture was extracted with dichloromethane (3X). The combined organics were washed with brine, dried (Na₂SO₄) and concentrated. Flash chromatography of the residue (silica gel;

25 dichloromethane/MeOH/10% aq. NH₄OH 90:2.5:2.5 to 90:5:5) provided the title product as a white foam (1.66g).

¹HNMR (500MHz, acetone-d₆): δ 0.60-0.88 (m, 4H), 3.48 (m, 1H), 3.58 (m, 1H), 3.90 (m, 1H), 4.90 (t, 1H), 6.79 (t, 1H), 7.01 (m, 1H), 7.12 (m, 2H), 7.22 (m, 1H), 7.49 (s, 1H), 7.86 (s, 1H), 7.95 (d, 1H), 8.09 (s, 1H), 8.33 (br s, 1H).

30

EXAMPLES 35 AND 36



5 CHIRAL 3-{2-[(3-CYCLOPROPYLOXY-4-DIFLUOROMETHOXY)PHENYL]-2-{5-[2-(1-HYDROXY-1-TRIFLUOROMETHYL-2,2,2-
10 TRIFLUORO)ETHYL]THIAZOLYL}ETHYL}PYRIDINE *N*-OXIDE

15 Examples 35 and 36 were prepared by the following procedure. A solution of the material from Example 34 (1.66g) in EtOH/hexane (20mL, 3:7) was injected (4 X 5mL) onto a Chiralpak® AD preparative (5cm X 50cm) HPLC column (eluting with hexane/EtOH 9:1 at 80mL/min with UV detection at 270nm). The enantiomers were separated with the faster eluting enantiomer having a retention time of ~16min (Enantiomer 1, Example 35) and the slower eluting enantiomer (Enantiomer 2, Example 36) having a retention time of ~19min. The eluants were concentrated to provide the enantiomers as white foams: Enantiomer 1 (652mg) and Enantiomer 2 (134mg).


20 ¹H NMR (500MHz, acetone-d₆) for each: δ 0.60-0.88 (m, 4H), 3.48 (m, 1H), 3.58 (m, 1H), 3.90 (m, 1H), 4.90 (t, 1H), 6.79 (t, 1H), 7.01 (m, 1H), 7.12 (m, 2H), 7.22 (m, 1H), 7.49 (s, 1H), 7.86 (s, 1H), 7.95 (d, 1H), 8.09 (s, 1H), 8.33 (br s, 1H).

25

Other variations or modifications, which will be obvious to those skilled in the art, are within the scope and teachings of this invention. This invention is not to be limited except as set forth in the following claims.

WHAT IS CLAIMED IS:

1. A compound represented by Formula (I):



5

(I)

or a pharmaceutically acceptable salt thereof, wherein

R¹ is C₁-6alkyl or C₃-6cycloalkyl, optionally substituted with 1-4 independent halogen;

R² is C₁-6alkyl or C₃-6cycloalkyl, optionally substituted with 1-4 independent halogen;

R³ is C₁-4alkyl, C₃-6cycloalkyl, heteroaryl, or phenyl, any of which optionally substituted independently with 1-4 independent halogen or C₁-6alkyl;

R⁴ is H or C₁-4alkyl, said alkyl optionally substituted with 1-4 independent halogen;

R^P is H, halogen, nitrile, or a C₁-6alkyl group, said alkyl optionally substituted with 1-4 independent halogen;

n is 0 or 1; and

when R³ and R⁴ are connected to each other through X, then R³ and R⁴ are each C₁alkyl, and X is C₀-4alkyl.

20

2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein

R¹ is C₁-6alkyl, optionally substituted with 1-4 independent halogen;

R² is C₁-6alkyl or C₃-6cycloalkyl, optionally substituted with 1-4

independent halogen;

R³ is C₁-4alkyl, C₃-6cycloalkyl, heteroaryl, or phenyl, any of which optionally substituted independently with 1-4 independent halogen or C₁-6alkyl;

R⁴ is H or C₁-4alkyl, said alkyl optionally substituted with 1-4 independent halogen;

5 R^P is H, halogen, nitrile, or a C₁-6alkyl group, said alkyl optionally substituted with 1-4 independent halogen;

n is 0 or 1; and

when R³ and R⁴ are connected to each other through X, then R³ and R⁴ are each C₁alkyl, and X is C₀-4alkyl.

10

3. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein

R¹ is C₁-6alkyl, optionally substituted with 1-4 independent halogen;

R² is C₁-6alkyl, optionally substituted with 1-4 independent halogen;

15

R³ is C₁-4alkyl, C₃-6cycloalkyl, heteroaryl, or phenyl, any of which optionally substituted independently with 1-4 independent halogen or C₁-6alkyl;

R⁴ is H or C₁-4alkyl, said alkyl optionally substituted with 1-4 independent halogen;

20

R^P is H, halogen, nitrile, or a C₁-6alkyl group, said alkyl optionally substituted with 1-4 independent halogen;

n is 0 or 1; and

when R³ and R⁴ are connected to each other through X, then R³ and R⁴ are each C₁alkyl, and X is C₀-4alkyl.

25

4. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein

R¹ is C₁-6alkyl, optionally substituted with 1-4 independent halogen;

R² is C₁-6alkyl, optionally substituted with 1-4 independent halogen;

30

R³ is C₁-4alkyl, optionally substituted independently with 1-4 independent halogen or C₁-6alkyl;

R⁴ is H or C₁-4alkyl, said alkyl optionally substituted with 1-4 independent halogen;

R^P is H, halogen, nitrile, or a C₁-6alkyl group, said alkyl optionally substituted with 1-4 independent halogen; and

35

n is 0 or 1.

5. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein

R¹ is C₁-6alkyl, optionally substituted with 1-4 independent halogen;

5 R² is C₁-6alkyl, optionally substituted with 1-4 independent halogen;

R³ is C₃-6cycloalkyl, optionally substituted independently with 1-4 independent halogen or C₁-6alkyl;

10 R⁴ is H or C₁-4alkyl, said alkyl optionally substituted with 1-4 independent halogen;

15 R^P is H, halogen, nitrile, or a C₁-6alkyl group, said alkyl optionally substituted with 1-4 independent halogen; and

n is 0 or 1.

6. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein

15 R¹ is C₁-6alkyl, optionally substituted with 1-4 independent halogen;

R² is C₁-6alkyl, optionally substituted with 1-4 independent halogen;

R³ is heteroaryl, optionally substituted independently with 1-4 independent halogen or C₁-6alkyl;

20 R⁴ is H or C₁-4alkyl, said alkyl optionally substituted with 1-4 independent halogen;

R^P is H, halogen, nitrile, or a C₁-6alkyl group, said alkyl optionally substituted with 1-4 independent halogen; and

n is 0 or 1.

25

7. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein

R¹ is C₁-6alkyl, optionally substituted with 1-4 independent halogen;

R² is C₁-6alkyl, optionally substituted with 1-4 independent halogen;

30 R³ is phenyl, optionally substituted independently with 1-4 independent halogen or C₁-6alkyl;

R⁴ is H or C₁-4alkyl, said alkyl optionally substituted with 1-4 independent halogen;

35 R^P is H, halogen, nitrile, or a C₁-6alkyl group, said alkyl optionally substituted with 1-4 independent halogen; and

n is 0 or 1.

8. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein

5 R¹ is C₁₋₆alkyl, optionally substituted with 1-4 independent halogen;
R² is C₁₋₆alkyl, optionally substituted with 1-4 independent halogen;
R³ and R⁴ are connected to each other through X;
R³ and R⁴ are each C₁alkyl;

X is C₀₋₄alkyl;

10 R^P is H, halogen, nitrile, or a C₁₋₆alkyl group, said alkyl optionally substituted with 1-4 independent halogen; and

n is 0 or 1.

9. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein

15 R¹ is C₁₋₆alkyl, optionally substituted with 1-4 independent halogen;

R² is C₃₋₆cycloalkyl, optionally substituted with 1-4 independent halogen;

R³ is C₁₋₄alkyl, C₃₋₆cycloalkyl, heteroaryl, or phenyl, any of which optionally substituted independently with 1-4 independent halogen or C₁₋₆alkyl;

20 R⁴ is H or C₁₋₄alkyl, said alkyl optionally substituted with 1-4 independent halogen;

R^P is H, halogen, nitrile, or a C₁₋₆alkyl group, said alkyl optionally substituted with 1-4 independent halogen;

n is 0 or 1; and

25 when R³ and R⁴ are connected to each other through X, then R³ and R⁴ are each C₁alkyl, and X is C₀₋₄alkyl.

10. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein

30 R¹ is C₁₋₆alkyl, optionally substituted with 1-4 independent halogen;

R² is C₃₋₆cycloalkyl, optionally substituted with 1-4 independent halogen;

R³ is C₁₋₄alkyl, optionally substituted independently with 1-4 independent halogen or C₁₋₆alkyl;

R⁴ is H or C₁₋₄alkyl, said alkyl optionally substituted with 1-4

35 independent halogen;

RP is H, halogen, nitrile, or a C₁-6alkyl group, said alkyl optionally substituted with 1-4 independent halogen; and
n is 0 or 1.

5 11. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein

R¹ is C₁-6alkyl, optionally substituted with 1-4 independent halogen;
R² is C₃-6cycloalkyl, optionally substituted with 1-4 independent halogen;
R³ is C₃-6cycloalkyl, optionally substituted independently with 1-4

10 independent halogen or C₁-6alkyl;

R⁴ is H or C₁-4alkyl, said alkyl optionally substituted with 1-4 independent halogen;

RP is H, halogen, nitrile, or a C₁-6alkyl group, said alkyl optionally substituted with 1-4 independent halogen; and

15 n is 0 or 1.

12. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein

R¹ is C₁-6alkyl, optionally substituted with 1-4 independent halogen;

20 R² is C₃-6cycloalkyl, optionally substituted with 1-4 independent halogen;

R³ is heteroalkyl, optionally substituted independently with 1-4 independent halogen or C₁-6alkyl;

R⁴ is H or C₁-4alkyl, said alkyl optionally substituted with 1-4 independent halogen;

25 RP is H, halogen, nitrile, or a C₁-6alkyl group, said alkyl optionally substituted with 1-4 independent halogen; and

n is 0 or 1.

30 13. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein

R¹ is C₁-6alkyl, optionally substituted with 1-4 independent halogen;

R² is C₃-6cycloalkyl, optionally substituted with 1-4 independent halogen;

R³ is phenyl, optionally substituted independently with 1-4 independent halogen or C₁-6alkyl;

R⁴ is H or C₁-4alkyl, said alkyl optionally substituted with 1-4 independent halogen;

R^P is H, halogen, nitrile, or a C₁-6alkyl group, said alkyl optionally substituted with 1-4 independent halogen; and

5 n is 0 or 1.

14. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein

R¹ is C₁-6alkyl, optionally substituted with 1-4 independent halogen;

10 R² is C₃-6cycloalkyl, optionally substituted with 1-4 independent halogen;

R³ and R⁴ are connected to each other through X;


R³ and R⁴ are each C₁alkyl;




X is C₀-4alkyl;




R^P is H, halogen, nitrile, or a C₁-6alkyl group, said alkyl optionally substituted with 1-4 independent halogen; and




15 n is 0 or 1.



15. The compound according to claim 1, comprising










































or a pharmaceutically acceptable salt thereof.

16. The compound according to claim 1, comprising

5 (\pm)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-hydroxy-1-methyl)ethyl)thiazolyl]ethyl}pyridine *N*-oxide;

 Chiral 4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-hydroxy-1-methyl)ethyl)thiazolyl]ethyl}pyridine *N*-oxide;

10 (\pm/\pm)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-hydroxy-2,2,2-trifluoroethyl)thiazolyl]ethyl}pyridine *N*-oxide;

 (\pm/\pm)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-hydroxy-2,2,2-trifluoroethyl)thiazolyl]ethyl}pyridine *N*-oxide;

 (\pm)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-[2-(1-hydroxy-1-trifluoromethyl-2,2,2-trifluoroethyl)thiazolyl]ethyl}pyridine;

15 (\pm)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-[2-(1-hydroxy-1-trifluoromethyl-2,2,2-trifluoroethyl)thiazolyl]ethyl}pyridine *N*-oxide;

 (\pm/\pm)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-[2-(1-hydroxy-1-trifluoromethyl)ethyl]thiazolyl]ethyl}pyridine *N*-oxide;

20 (\pm/\pm)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-phenylmethanol)thiazolyl]ethyl}pyridine *N*-oxide;

 (\pm/\pm)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-hydroxy-1-phenyl)ethyl)thiazolyl]ethyl}pyridine *N*-oxide;

 (\pm/\pm)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-hydroxy-1-phenyl-2,2,2-trifluoroethyl)thiazolyl]ethyl}pyridine *N*-oxide;

(\pm/\pm)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-hydroxy-1-phenyl)propyl)thiazolyl]ethyl}pyridine *N*-oxide;

(\pm/\pm)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-cyclohexylmethanol)thiazolyl]ethyl}pyridine;

5 (\pm/\pm)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-hydroxy-1-cyclohexyl-2,2,2-trifluoromethyl)ethyl)thiazolyl]ethyl}pyridine *N*-oxide;

(\pm/\pm)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-hydroxy-1-(4-ethyl)phenyl)ethyl)thiazolyl]ethyl}pyridine *N*-oxide;

10 (\pm/\pm)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-hydroxy-1-(4-ethyl)phenyl-2,2,2-trifluoro)ethyl)thiazolyl]ethyl}pyridine *N*-oxide;

(\pm/\pm)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-hydroxy-1-(4-fluoro)phenyl)ethyl)thiazolyl]ethyl}pyridine *N*-oxide;

15 (\pm/\pm)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-hydroxy-1-(4-fluoro)phenyl-2,2,2-trifluoro)ethyl)thiazolyl]ethyl}pyridine *N*-oxide;

(\pm/\pm)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-hydroxy-1-(5-bromopyridin-2-yl)-2,2,2-trifluoro)ethyl)thiazolyl]ethyl}pyridine *N*-oxide;

(\pm/\pm)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-(2-(1-hydroxy-1-(6-bromopyridin-3-yl)-2,2,2-trifluoro)ethyl)thiazolyl]ethyl}pyridine *N*-oxide;

20 (\pm)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-[2-(1-hydroxy)cyclobutyl]thiazolyl]ethyl}pyridine *N*-oxide;

(\pm)-4-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[5-[2-(1-hydroxy)cyclohexyl]thiazolyl]ethyl}pyridine *N*-oxide;

(\pm)-4-{2-[(3-cyclobutoxy-4-difluoromethoxy)phenyl]-2-[5-[2-(1-hydroxy-1-methyl)ethyl]thiazolyl]ethyl}pyridine *N*-oxide;

25 chiral 4-{2-[(3-cyclobutoxy-4-difluoromethoxy)phenyl]-2-[5-[2-(1-hydroxy-1-methyl)ethyl]thiazolyl]ethyl}pyridine *N*-oxide;

(\pm)-4-{2-[(3-cyclobutoxy-4-difluoromethoxy)phenyl]-2-[5-[2-(1-hydroxy-1-trifluoromethyl-2,2,2-trifluoro)ethyl]thiazolyl]ethyl}pyridine;

(\pm)-4-{2-[(3-cyclobutoxy-4-difluoromethoxy)phenyl]-2-[5-[2-(1-hydroxy-1-trifluoromethyl-2,2,2-trifluoro)ethyl]thiazolyl]ethyl}pyridine *N*-oxide;

30 Chiral 3-{2-[(3-cyclobutoxy-4-difluoromethoxy)phenyl]-2-[5-[2-(1-hydroxy-1-methyl)ethyl]thiazolyl]ethyl}pyridine;

Chiral 3-{2-[(3-cyclobutoxy-4-difluoromethoxy)phenyl]-2-[5-[2-(1-hydroxy-1-methyl)ethyl]thiazolyl]ethyl}pyridine *N*-oxide;

Chiral 3-[2-[(3-cyclobutyloxy-4-difluoromethoxy)phenyl]-2-{5-[2-(1-hydroxy-1-methyl)ethyl]thiazolyl}ethyl]pyridine *N*-oxide;

Chiral 3-[2-[(3-cyclobutyloxy-4-difluoromethoxy)phenyl]-2-{5-[2-(1-hydroxy-1-trifluoromethyl-2,2,2-trifluoro)ethyl]thiazolyl}ethyl]pyridine *N*-oxide;

5 (±)-2-[2-[(3-cyclobutyloxy-4-difluoromethoxy)phenyl]-2-{5-[2-(1-hydroxy-1-trifluoromethyl-2,2,2-trifluoro)ethyl]thiazolyl}ethyl]pyridine *N*-oxide;

(±)-4-[2-[(3-cyclopropyloxy-4-difluoromethoxy)phenyl]-2-{5-[2-(1-hydroxy-1-methyl)ethyl]thiazolyl}ethyl]pyridine *N*-oxide;

10 (±)-3-[2-[(3-cyclopropyloxy-4-difluoromethoxy)phenyl]-2-{5-[2-(1-hydroxy-1-trifluoromethyl-2,2,2-trifluoro)ethyl]thiazolyl}ethyl]pyridine *N*-oxide;
chiral 3-[2-[(3-cyclopropyloxy-4-difluoromethoxy)phenyl]-2-{5-[2-(1-hydroxy-1-trifluoromethyl-2,2,2-trifluoro)ethyl]thiazolyl}ethyl]pyridine *N*-oxide;
or a pharmaceutically acceptable salt thereof.

15 17. A pharmaceutical composition comprising
a therapeutically effective amount of the compound of Formula (I)
according to any one of claims 1 to 16, or a pharmaceutically acceptable salt
thereof; and, a pharmaceutically acceptable carrier.

20 18. The pharmaceutical composition according to claim 17, further
comprising a Leukotriene receptor antagonist, a Leukotriene biosynthesis inhibitor, or an
M2/M3 antagonist.

25 19. A method of treatment or prevention of asthma, chronic bronchitis,
chronic obstructive pulmonary disease, eosinophilic granuloma, psoriasis and other
benign or malignant proliferative skin diseases, endotoxic shock, laminitis in horses, colic
in horses, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the
myocardium and brain, inflammatory arthritis, chronic glomerulonephritis, atopic
dermatitis, urticaria, adult respiratory distress syndrome, infant respiratory distress
30 syndrome, chronic obstructive pulmonary disease in animals, diabetes insipidus, allergic
rhinitis, allergic conjunctivitis, vernal conjunctivitis, arterial restenosis, ortherosclerosis,
atherosclerosis, neurogenic inflammation, pain, cough, rheumatoid arthritis, ankylosing
spondylitis, transplant rejection, graft versus host disease, hypersecretion of gastric acid,
bacterial, fungal induced sepsis, viral induced sepsis, fungal induced septic shock, viral
35 induced septic shock, inflammation-mediated chronic tissue degeneration, cytokine-

mediated chronic tissue degeneration, osteoarthritis, cancer, cachexia, muscle wasting, depression, memory impairment, tumour growth, or cancerous invasion of normal tissues, osteoporosis, or bone loss, comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the 5 compound according to claim 1 or a pharmaceutically acceptable salt thereof.

20. Use of a compound of Formula (I), according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prevention of asthma, chronic bronchitis, 10 chronic obstructive pulmonary disease, eosinophilic granuloma, psoriasis and other benign or malignant proliferative skin diseases, endotoxic shock, laminitis in horses, colic in horses, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, inflammatory arthritis, chronic glomerulonephritis, atopic dermatitis, urticaria, adult respiratory distress syndrome, infant respiratory distress syndrome, chronic obstructive pulmonary disease in animals, diabetes insipidus, allergic rhinitis, allergic conjunctivitis, 15 vernal conjunctivitis, arterial restenosis, ortherosclerosis, atherosclerosis, neurogenic inflammation, pain, cough, rheumatoid arthritis, ankylosing spondylitis, transplant rejection, graft versus host disease, hypersecretion of 20 gastric acid, bacterial, fungal induced sepsis, viral induced sepsis, fungal induced septic shock, viral induced septic shock, inflammation-mediated chronic tissue degeneration, cytokine-mediated chronic tissue degeneration, osteoarthritis, cancer, cachexia, muscle wasting, depression, memory impairment, tumour growth, or cancerous invasion of normal tissues, osteoporosis, or bone loss.

25

21. A compound of Formula (I), as defined in any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof for use as a phosphodiesterase-4 inhibitor.

22. A phosphodiesterase-4 inhibitor pharmaceutical composition comprising an acceptable phosphodiesterase-4 inhibiting amount of a compound of Formula (I), as defined in any one of claims 1 to 16, in association with a pharmaceutically acceptable carrier.

5

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 September 2001 (27.09.2001)

PCT

(10) International Publication Number
WO 01/070738 A3

(51) International Patent Classification⁷: C07D 417/08,
A61P 37/00, C07D 417/06, 417/14, A61K 31/427

31.1 (CA). **FRENETTE, Richard** [CA/CA]; 16711
Trans-Canada Highway, Kirkland, Québec H9H 3L1 (CA).
LALIBERTE, Sébastien [CA/CA]; 16711 Trans-Canada
Highway, Kirkland, Québec H9H 3L1 (CA).

(21) International Application Number: PCT/CA01/00365

(74) Agents: **MURPHY, Kevin, P. et al.**; SWABEY OGILVY
RENAULT, Suite 1600, 1981 McGill College Avenue,
Montreal, Québec H3A 2Y3 (CA).

(22) International Filing Date: 19 March 2001 (19.03.2001)

(25) Filing Language: English

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(26) Publication Language: English

(30) Priority Data:

60/191,668 23 March 2000 (23.03.2000) US

(71) Applicant (for all designated States except US):
MERCK FROSST CANADA & CO. [CA/CA]; 16711
Trans-Canada Highway, Kirkland, Québec H9H 3L1 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **FRIESEN, Richard**
[CA/CA]; 16711 Trans-Canada Highway, Kirkland,
Québec H9H 3L1 (CA). **DUCHARME, Yves** [CA/CA];
16711 Trans-Canada Highway, Kirkland, Québec H9H 3L1
(CA). **COTE, Bernard** [CA/CA]; 16711 Trans-Canada
Highway, Kirkland, Québec H9H 3L1 (CA). **BLOUIN,**
Marc [CA/CA]; 16711 Trans-Canada Highway, Kirkland,
Québec H9H 3L1 (CA). **MARTINS, Evelyn** [CA/CA];
16711 Trans-Canada Highway, Kirkland, Québec H9H
3L1 (CA). **GUAY, Daniel** [CA/CA]; 16711 Trans-Canada
Highway, Kirkland, Québec H9H 3L1 (CA). **HAMEL,**
Pierre [CA/CA]; 16711 Trans-Canada Highway, Kirk-
land, Québec H9H 3L1 (CA). **GIRARD, Mario** [CA/CA];
16711 Trans-Canada Highway, Kirkland, Québec H9H

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CI,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
1 August 2002

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.



WO 01/070738 A3

(54) Title: TRI-ARYL-SUBSTITUTED-ETHANE PDE4 INHIBITORS

(57) Abstract: Novel ethanes substituted with i) a phenyl, ii) a thiazole, and iii) a pyridyl moiety are PDE4 inhibitors.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 01/00365

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C07D417/08 A61P37/00 C07D417/06 C07D417/14 A61K31/427

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 C07D

[No information is available other than minimum documentation to the extent that such documents are included in the fields searched]

[No trade data base consulted during the international search (name of data base and, where practical, search terms used)]

EPO-Internal, CHEM ABS Data, PAJ, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	1. Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 710 170 A (BLOUIN MARC ET AL) 20 January 1998 (1998-01-20) cited in the application column 1, line 11 column 2, formula I column 3, line 27 - line 31 column 3, line 45 column 4, line 17-23 column 7, line 33-44 -----	1-22

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

12 March 2002

Date of mailing of the international search report

19/03/2002

Name and mailing address of the ISA

 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Hoepfner, W

INTERNATIONAL SEARCH REPORT

Information on patent family members

National Application No

PCT/CA 01/00365

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US 5710170	A 20-01-1998	AU	707574 B2	15-07-1999
		AU	1028097 A	14-07-1997
		CA	2238875 A1	26-06-1997
		WO	9722586 A1	26-06-1997
		EP	0873311 A1	28-10-1998
		JP	2000501742 T	15-02-2000

